WO2021145742A1 - Composition for improving athletic function, comprising phlorotannin as active ingredient - Google Patents

Composition for improving athletic function, comprising phlorotannin as active ingredient Download PDF

Info

Publication number
WO2021145742A1
WO2021145742A1 PCT/KR2021/000645 KR2021000645W WO2021145742A1 WO 2021145742 A1 WO2021145742 A1 WO 2021145742A1 KR 2021000645 W KR2021000645 W KR 2021000645W WO 2021145742 A1 WO2021145742 A1 WO 2021145742A1
Authority
WO
WIPO (PCT)
Prior art keywords
ecklonia
composition
formula
improving
phlorotannin
Prior art date
Application number
PCT/KR2021/000645
Other languages
French (fr)
Korean (ko)
Inventor
이행우
신현철
오재근
Original Assignee
주식회사 만나스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020200006556A external-priority patent/KR20210093408A/en
Priority claimed from KR1020210005925A external-priority patent/KR102594284B1/en
Application filed by 주식회사 만나스 filed Critical 주식회사 만나스
Publication of WO2021145742A1 publication Critical patent/WO2021145742A1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02Algae
    • A61K36/03Phaeophycota or phaeophyta (brown algae), e.g. Fucus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system

Definitions

  • the present invention relates to a composition for improving motor function of humans, particularly those aged 60 years or older, and a product comprising the same, and to a composition comprising a specific combination of Ekcol-based compounds and having an effect of improving reduced motor function and a product comprising the same it's about
  • the human musculoskeletal system is a system that enables human movement. Anatomically, it consists of bones, muscles, cartilage, ligaments, etc., and exists as an integrated system throughout the human body through the vascular system, the nervous system and the immune system. do.
  • the health of the musculoskeletal system is an essential element of life that enables human beings to live independently.
  • body protection, dynamic function, and beauty can be made possible by controlling the magnitude and strength of the movement of the extremities and performing flexible and balanced movements.
  • the normal function of the musculoskeletal system is absolutely important for survival and human dignity, as well as for physical beauty, athletics and artistic dimensions.
  • musculoskeletal dysfunction due to trauma can be recovered by appropriate surgical and physical therapy procedures, except for cases that cause disability.
  • one or more elements constituting the musculoskeletal system enter into a chronic exacerbation process due to after-traumatic trauma, chronic stress, and aging, the functional range of the musculoskeletal system is reduced, and again the normal function of the musculoskeletal system is reduced, such as decreased muscle mass, decreased bone density, decreased peripheral blood flow, etc.
  • Motor function gradually deteriorates through positive feedback in such a way that structural elements necessary for functional implementation deteriorate, and eventually, various risks are exposed and the quality of life is greatly reduced.
  • the present inventors recognized the need for a more integrated approach in a method of improving motor function through recovery of musculoskeletal function, and studied a motor function improvement model linked to musculoskeletal function as shown in FIG. 1 .
  • essential physical elements that the musculoskeletal system must have for smooth movement functions of the human body, including the ability to walk upright, were analyzed into three categories: strength, flexibility, and sense of balance of musculoskeletal tissue. When any one of these three factors worsens, the function of the musculoskeletal system gradually deteriorates in a way that adversely affects the other factors, resulting in a rapid decline in motor function.
  • the present inventors intend to provide a composition and product that can be expected to improve the motor function of humans, especially those aged 60 years or older, by exerting an overall improvement effect on the musculoskeletal system by easily ingesting it with confidence.
  • the present invention provides a composition for enhancing or improving exercise function comprising a phlorotannin compound as an active ingredient.
  • the present invention provides a composition for enhancing or improving motor function by improving at least one of musculoskeletal tissue, flexibility, and sense of balance.
  • the present invention provides a composition for enhancing or improving athletic function by improving at least one of muscle mass and bone density.
  • the present invention provides a product for enhancing or improving exercise function comprising the composition.
  • compositions and products containing phlorotannin as an active ingredient of the present invention are safe and easy to use as a natural material, and improve the musculoskeletal tissue, flexibility and sense of balance, which are three aspects essential for the smooth functioning of the musculoskeletal system, by using a small amount. It has the effect of enhancing and improving motor function.
  • Compositions and products containing phlorotannin as an active ingredient of the present invention are particularly effective in improving muscle mass and/or bone density.
  • FIG. 1 shows a model for improving motor function linked to a musculoskeletal system function.
  • Figure 2 shows the organic relationship between the process of deterioration of motor function due to the weakening of the musculoskeletal system and related factors.
  • the present invention provides a composition for enhancing or improving exercise function comprising a phlorotannin compound as an active ingredient.
  • the present invention provides a composition capable of enhancing or improving motor function through restoration of musculoskeletal function.
  • the present invention provides a composition that enhances and improves motor function through improvement of three aspects essential for smooth functioning of the musculoskeletal system: musculoskeletal tissue, flexibility, and sense of balance.
  • stem cells Stemcells in the case of muscle; satellite cells in the case of bone
  • NFkB a redox-sensitive transcriptional factor in mesenchymal stem cells
  • oxidative stress in the musculoskeletal system increases, the regeneration rate is reduced compared to the decomposition rate of muscle and bone tissue, blood flow decreases, and dehydration of cells occurs, thereby entering a vicious cycle of deterioration and degeneration of the musculoskeletal system.
  • the present inventors effectively break this vicious circle and while seeking an effective method to generate a virtuous cycle, the process of the vicious cycle of musculoskeletal function deterioration, from the cause-providing stage (increased cellular stress), to the biochemical risk amplification stage (excessive immune activity) increase) and physiological risk (decreased peripheral blood flow) and physical function decline (muscle reduction, bone density decrease, neurotransmitter function decreased) were classified into 4 stages, and effective reversal of each stage was performed for the reduced musculoskeletal system. It was identified as an essential element to restore function.
  • composition containing phlorotannins having various structures and activities as an active ingredient can achieve this purpose while searching for a component having this effect among natural ingredients that are harmless to the human body. That is, it was confirmed that the composition containing phlorotannin as an active ingredient can improve the overall function of the musculoskeletal system, that is, the motor function, and completed the present invention. In particular, it was confirmed that the composition containing phlorotannin as an active ingredient can solve senile sarcopenia and completed the present invention.
  • the composition of the present invention is a phlorotannin composition optimized for cellular stress reduction activity, immune balance tuning activity, blood circulation promoting activity and neurotransmission promoting activity, and simultaneously provides the three elements of motor function, musculoskeletal tissue, flexibility, and balance, without side effects. can be improved within.
  • the composition of the present invention can improve the function of the musculoskeletal system by improving at least one of muscle mass and bone density, particularly both muscle mass and bone density, and, as a result, can improve exercise function.
  • the composition of the present invention can improve the motor function of the elderly by simultaneously improving the muscle mass and bone density of the elderly over 60 years of age.
  • composition of the present invention can exhibit further effects by ingesting the composition in the form of an aqueous solution under specific conditions (concentration, intake amount, time of intake).
  • Phlorotannin included in the composition for improving motor function by restoring musculoskeletal function of the present invention can be obtained by any conventional method, can also be synthesized using commercially available reagents, and can be obtained by extraction and separation from natural products, particularly seaweed. may be
  • Phlorotannin an active ingredient of the composition of the present invention, can be extracted from brown algae, specifically rhubarb (Eisenia bicyclis), Eisenia arborea (Eisenia arborea), Eisenia desmarestioides (Eisenia desmarestioides), children Eisenia galapagensis, Eisenia masonii, Ecklonia kurome, Ecklonia cava, Ecklonia stolonifera, sea bamboo (Ecklonia maxima), Ecklonia radiata (Ecklonia radiata), Ecklonia bicyclis, Ecklonia biruncinate, Ecklonia buccinalis, Ecklonia caepaestipes, Ecklonia exas Ecklonia exasperta, Ecklonia fastigiata, Ecklonia brevipes, Ecklonia arborea, Ecklonia latifolia, Ecklonia murati Ecklonia muratii), Ecklonia radicosa, Ecklonia richardiana, and Ecklonia wrightii may be
  • the phlorotannin compound is preferably an Ekcol-based compound represented by the following Chemical Formula 1-12 among phlorotannin compounds.
  • Ekkol-based compounds have a relatively small molecular weight, and have a three or five fused ring system, with a hard and flat planar structure, and di-hydroxyphenyl or tri-hydroxyphenol ( Because it can have various conformations through free rotation of tri-hydroxyphenyl) groups, various physiological activities can be exhibited according to the specific structure of each compound in various tissues of the human body.
  • the phlorotannin compound which is an active ingredient of the composition of the present invention, may more preferably be at least one compound selected from compounds of the following Chemical Formulas 1 to 12.
  • the composition for improving exercise function of the present invention may contain 0.001-100% by weight of the phlorotannin compound, preferably 0.1-100% by weight.
  • the composition for improving exercise function of the present invention may contain 0-99.999% by weight of water.
  • the composition of the present invention contains at least one phlorotannin selected from Chemical Formula 7, which is excellent in cell stress reducing activity, and Chemical Formula 1 to 6, which has excellent immune balance promoting activity and blood circulation promoting activity, and Chemical Formula 8 to excellent neurotransmission promoting activity.
  • Chemical Formula 7 which is excellent in cell stress reducing activity
  • Chemical Formula 1 to 6 which has excellent immune balance promoting activity and blood circulation promoting activity
  • Chemical Formula 8 to excellent neurotransmission promoting activity.
  • the composition for improving motor function of the present invention is preferably at least one phlorotannin selected from phlorotannins of Chemical Formula 7 and Chemical Formulas 1 to 6, and at least one phlorotannin selected from Chemical Formulas 8 to 12 phlorotannin.
  • rotannin is contained in 5-50%, 15-65%, and 10-50% by weight, respectively, cellular stress reduction activity, immune balance promoting activity, blood circulation promoting activity, and neurotransmission promoting activity necessary for recovery of musculoskeletal function are simultaneously and synergistic. As a result, it can exert its effect in a negative way, resulting in the improvement of motor function.
  • the composition for improving exercise function of the present invention comprises 15 to 40% by weight of phlorotannin of Formula 2, 5 to 50% by weight of phlorotannin of Formula 7, and 10 to 50% by weight of phlorotannin of Formula 10 with respect to the total weight
  • the composition for improving exercise function of the present invention is 1 to 35% by weight of phlorotannin of Formula 1, 1 to 50% by weight of phlorotannin of Formula 2, 1 to 50% by weight of phlorotannin of Formula 3, with respect to the total weight of the composition for improving exercise function of the present invention Phlorotannin of 0.5 to 10% by weight of 4, phlorotannin of 0.5 to 10% by weight of Formula 5, phlorotannin of 0.5 to 10% by weight of Formula 6, phlorotannin of 15 to 65% by weight of Formula 7, Formula 8 Phlorotannin 0.1 to 20% by weight, phlorotannin 0.1 to 20% by weight of Formula 9, phlorotannin 1 to 30% by weight of Formula 10, phlorotannin 1 to 20% by weight of Formula 11, and fluoro of Formula 12 If 0.1 to 20% by weight of tannins are included, it may bring about an effect of improving exercise function.
  • the composition of the present invention When the composition of the present invention is ingested as an aqueous solution, the effect may be excellent.
  • the composition of the present invention contains phlorotannin at a concentration of 0.1 to 100 ppm, preferably 10 to 200 mL, preferably 50 to 200 mL, in an aqueous solution of 1-100 ppm at a concentration of 20 to 50 ° C.
  • the esophagus, small intestine, Absorption in the entire gastrointestinal tract, including the large intestine is accelerated, improving the musculoskeletal system and improving motor function.
  • composition for improving exercise function of the present invention can be consumed on an empty stomach or with food and beverages and after a meal, but it is more effective when taken on an empty stomach, particularly right after waking up in the morning, or during a rest period of the human body, such as just before going to bed in the evening.
  • the present invention provides a product for enhancing or improving exercise function comprising the composition for improving exercise function.
  • the product for improving exercise function containing the phlorotannin may be commercialized in the form of a liquid, powder, effervescent tablet, protein bar, capsule, etc., but is not limited thereto.
  • the product for improving exercise function containing phlorotannin of the present invention is provided in a liquid form and ingested, or in the form of a powder or effervescent tablet dissolved in water, absorption in the gastrointestinal tract is promoted and musculoskeletal function is provided. can improve motor function as a result.
  • the product for improving exercise function containing phlorotannin of the present invention is provided in the form of a protein bar or capsule, it is preferable to consume it with sufficient water to promote absorption.
  • the product of the present invention contains phlorotannin at a concentration of 0.1 to 100 ppm, preferably at a concentration of 1-100 ppm, in an aqueous solution at 20-50 ° C. 10 to 200 mL, preferably 50 to 200 mL, when ingested at a time, esophagus, small intestine, large intestine Absorption in the entire gastrointestinal tract is promoted, thereby improving the musculoskeletal system function, thereby improving motor function.
  • the product of the present invention contains at least one selected from the group consisting of protein, glycosidal saponin, inositol, glucomanan, dextrin, amino acids, inorganic salts and vitamins as an auxiliary component together with a composition for improving exercise function containing phlorotannin. If it is further included, it is possible to improve the musculoskeletal system function.
  • the daily usage of phlorotannin contained in the composition and product for improving exercise function of the present invention is preferably about 0.1 to 100 mg based on a 50 kg adult, but the usage is not limited to the above range.
  • the product for improving motor function of the present invention can improve muscle mass, bone density, flexibility and sense of balance when ingested in a liquid form containing 1 to 100 ppm of phlorotannin compound, 10 to 2000 mL, preferably 50 to 500 mL per day. there is.
  • composition containing phlorotannin as an active ingredient of the present invention was extracted from Ecklonia cava , a brown algae collected near Jeju Island, by the following method.
  • Ecklonia cava was washed with distilled water to remove foreign substances, dried in the shade, and crushed. Put 5 kg of Ecklonia cava in an extraction container, and 20 times the weight of Ecklonia cava, 30% by weight aqueous solution of alcohol was added, and extracted under reflux at 75 to 80° C. for 4 hours to obtain an extract. The extract was filtered through a 10 ⁇ m filter, and the filtered extract was concentrated under reduced pressure in a water bath at 55° C. to obtain a primary extract concentrate. The primary extract concentrate was dried in a vacuum dryer at 90° C. for at least 8 hours at a pressure of 70 torr, and then pulverized to obtain 1700 g of the primary extract.
  • the primary extract was dissolved in hot water at 50° C., adsorbed on an adsorption resin, washed with water, and eluted with alcohol to obtain a phlorotannin eluate.
  • the eluate was filtered through a 1 ⁇ m filter, and the filtered extract was concentrated under reduced pressure in a water bath at 55° C. to obtain a secondary extract concentrate.
  • the secondary extract concentrate was dried in a vacuum dryer at 90° C. for at least 8 hours at a pressure of 70 torr, and then pulverized to obtain 300 g of the secondary extract.
  • the secondary extract was dissolved in alcohol, and filter aid (diatomaceous earth or bentonite) was added and filtered to obtain an eluate.
  • the eluate was filtered through a 1 ⁇ m filter, and the filtered eluate was concentrated under reduced pressure in a water bath at 55°C to obtain a concentrate.
  • the concentrate was dried in a vacuum dryer at 90° C. for at least 8 hours at a pressure of 70 torr, and then pulverized to obtain 190 g of a tertiary extract.
  • the tertiary extract obtained above was loaded on liquid chromatography to proceed with compound separation to obtain 104 g, 18 g and 33 g of phlorotannin fractions I, II and III, respectively.
  • each of the three fractions obtained was dissolved in 60% methanol, filtered with 0.2 ⁇ m membrane filter paper, and loaded into high performance liquid chromatography.
  • the column was HP ODS Hypersil, the solvent was distilled water and methanol, and the solvent was supplied at a flow rate of 1.0 ml/min. From 15% to 70% of methanol, a linear gradient was performed over 30 minutes. Then, compounds of Formulas 1 to 12 were obtained, which were identified by NMR or the like.
  • the dry weight of the separated compound is shown in Table 1 below.
  • Formula 1 Formula 2 Formula 3
  • Formula 4 Formula 5
  • Formula 6 Formula 7
  • Formula 8 Formula 9
  • Formula 10 Formula 11
  • Weight 20.0 26.1 17.9 14.8 9.0 8.4 13.9
  • ER Stress-reducing activity The effect on ER Stress, which refers to stress at the cellular level, was measured.
  • 1000 nM of Thapsigargin which is well known to cause apoptosis by ER stress, was added and treated for 24 hours, followed by MTT (3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) solution treatment (2h, 37°C, 5% CO2) and formazan production was measured at 540nm to measure the degree of apoptosis relief for each compound.
  • Immune balancing activity Aging is accompanied by chronic inflammation and disrupts the immune balance.
  • Biochemically since NFkB, an inflammation-inducing transcription factor, is chronically activated and induces degeneration of musculoskeletal tissue, the degree of activation of NFkB was measured.
  • RAW 264.7 macrophage cell line was transfected with NFkB-Luc reporter plasmid (Clontech, Shiga, Japan), treated with 10 ⁇ M of each compound of Formula 1-12 for 1 hour, and then treated with LPS (1 ⁇ g/mL) for 24 hours. NFkB activation was measured by measuring luciferase activity.
  • Blood circulation promoting activity Aging causes the tendency of blood to overcoagulate and physiologically decreases blood circulation, thereby reducing homeostasis of musculoskeletal tissue and contributing to degeneration. Therefore, aPTT, a representative index of blood coagulation rate, was measured. After mixing 10 ⁇ L of each of the compounds of Formulas 1 to 12 at a concentration of 100 ⁇ M in citric acid-treated normal human plasma (90 ⁇ L), the mixture was left at 37° C. for 1 minute. Then, after adding 100 ⁇ L of aPTT assay reagent (Fisher Diagnostics, USA), it was left at 37° C. for 1 minute, and then 20 mM CaCl 2 (100 ⁇ L) was added to measure the time (seconds) required for coagulation.
  • aPTT assay reagent (Fisher Diagnostics, USA)
  • Acetylcholine a neurotransmitter, is required to trigger the movement of musculoskeletal tissue, and acetylcholine is insufficient in the nerves of aging tissues. Therefore, the inhibitory activity on acetylcholine hydrolase (AChE) that degrades acetylcholine was measured.
  • AChE acetylcholine hydrolase
  • DTNB 5,5'-dithiobis(2-nitrobenzoic acid) solution (900 ⁇ L of 5.55mM DTNB in 50mM potassium phosphate buffer, pH 7.4), ATCh (Acetylthiocholine chloride) solution (2mM ATCh, 25 ⁇ L) and 1mM concentration of Formula 1 ⁇
  • ATCh Alcoholthiocholine chloride
  • compositions and dextrin were mixed in a weight ratio of 1:99 to prepare Product Examples 1 to 9 each containing 1% of the compositions 1 to 9. Since all the compositions had no particular taste, but had a pale yellow color, a small amount of caramel pigment was added to the dextrin to prepare a placebo product (Comparative Product Example 1) in which walking and taste were indistinguishable from the composition.
  • T-score bone density
  • %FFMI muscle mass
  • Lower extremity flexibility (left flexion: Sit & Reach Flexibility Test) was measured as follows. Sitting on a 40 cm high measuring table with both feet spread 5 cm apart, the Trunk Flexion Tester was pushed to the maximum. Shaking the upper body, the body was not bent forward by the recoil, and the knee was kept straight during measurement. Also, the tip of one hand was placed on the same line as the tip of the other, and when the upper body was bent forward, the head was placed between the arms. The unit was set to 0.1 cm, and the best record was selected as a result of three measurements.
  • the one-legged test can quantitatively measure postural balance and is a convenient method (Rossiter-Fornoff, Wolf, Wolfson, Buchner & FICSIT Group, The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 50 ( 6), M291 -M297 (1995), in this study, the leg was lifted backward, the knee joint was bent at 90 degrees, both eyes were open, and the time until the foot of the raised leg touched the ground was measured. A total of two measurements were taken and the highest record was used.
  • Preparation and intake method of test drink Every evening, put Product Examples 1 to 9 or Comparative Product Example 1 into a 500 mL thermos in the same amount as one plastic spoon (700 mg capacity) provided in advance, and put it at 40-50 ° C. 500mL of mineral water was added, the lid was closed, and completely dissolved by shaking. Immediately after waking up the next day, 150 mL was taken on an empty stomach, a total of 200 mL was freely ingested between meals, and the remaining 150 mL was taken on an empty stomach before bedtime. The temperature of the solution at the time of ingestion was in the range of 25-40 °C. The results are shown in Table 4 below.
  • composition 8 was administered in 3 concentrations of aqueous solution (1ppm, 20ppm and 100ppm, 200mL ingestion at a time, aqueous solution temperature 15 ⁇ 25°C) and capsules (90mg per capsule, 1time) 2 capsules were taken in the form of 200mL of room temperature water (15 ⁇ 25°C) every day for 7 days immediately after waking up and right before going to bed, and the improvement of trunk muscle function compared to before intake was evaluated.
  • Humac NORM CSMi Co., USA
  • Humac NORM CSMi Co., USA
  • Humac NORM CSMi Co., USA
  • Warm-up exercises were performed freely for ⁇ 10 minutes.
  • the chest, pelvic, and knee were firmly fixed using a strap, a belt, and a fixed pad.
  • Gravity reduction was performed so that gravity caused by the body mass was not reflected during measurement, and the range of motion (ROM) during measurement was extended from -10° ⁇ to flexion 60°.
  • Trunk flexion and extension strength were measured 4 times at 30°/sec, 4 times at 60°/sec, and 4 times at 90°/sec, and peak torque (Nm) was measured per body weight (%BW). did.
  • Adaptation exercises were performed 4 times for each angular velocity, and the rest time between measurements was set to 20 seconds.
  • Daily intake of composition 9 0.4 mg 8 mg 40mg 360mg Trunk flexion maximum force @30 degrees/sec 19.7 25.3 27.4 15.3 Trunk extension maximum force @30 degrees/sec 18.8 23.1 24.9 14.2 Trunk flexion maximum force @60 degrees/sec 19.1 24.7 22.2 13.4 Trunk extension maximum force @60 degrees/sec 10.8 17.4 21.3 9.2 Trunk Bend Maximum Couple @90 degrees/sec 22.6 27.9 29.0 15.3 Trunk extension max. force @90 degrees/sec 21.5 29.3 31.3 16.4 total improvement 112.5 147.7 156.1 83.8
  • Total daily intake (mg) 10.0 10.0 10.0 10.0 10.0 10.0 10.0 Concentration of composition in aqueous solution (ppm) 100 50 33.3 25 Capsules with 5mg Serving amount (mL) of aqueous composition 50 100 150 200 Take with 150mL of water Improvement rate of left abduction compared to before intake (%) 12.8 22.7 27.5 20.8 2.3
  • product example 7 drinks (25ppm concentration, total 300mL) were administered in two ways for one week each - (1) Two times in the daytime (1 time between breakfast and lunch) , between lunch and dinner) and (2) immediately after waking up in the morning + before going to bed in the evening - twice a time, 150mL each, and the degree of improvement in motor function compared with before intake was evaluated. The results are shown in Table 7. As a result, the method (2) showed a superior improvement effect. Therefore, it was found that the injection of the composition into the gastrointestinal tract during the resting period of the human body is more effective than the input during the active period.
  • composition of the present invention can be used to improve exercise function by comprehensively improving the functions of the musculoskeletal system through oral intake, and in particular, when the product of the present invention is ingested, bone density, muscle mass, flexibility and sense of balance are overall improved, It can improve the quality of sports and artistic activities.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a composition having the effect of improving athletic function by comprehensively improving the function of the musculoskeletal system through oral ingestion. More specifically, the present invention relates to a composition comprising a phlorotannin compound as an active ingredient, and related products, which can be ingested in a beverage form to comprehensively improve bone density, bone mass, flexibility, and equilibrioception, and thus can be used to contribute to increasing the quality of living, sports, and artistic activity that essentially require the successful functioning of the musculoskeletal system.

Description

[규칙 제26조에 의한 보정 05.02.2021] 플로로탄닌을 유효성분으로 포함하는 운동 기능 개선용 조성물 [Correction 05.02.2021 according to Rule 26]   Composition for improving exercise function containing phlorotannin as an active ingredient
본 발명은 사람 특히 60세 이상 노인의 운동 기능 개선용 조성물 및 이를 포함하는 제품에 대한 것으로, 엑콜계 화합물의 특정한 조합으로 구성되어 저하된 운동 기능을 개선하는 효과를 갖는 조성물 및 이를 포함하는 제품에 관한 것이다.The present invention relates to a composition for improving motor function of humans, particularly those aged 60 years or older, and a product comprising the same, and to a composition comprising a specific combination of Ekcol-based compounds and having an effect of improving reduced motor function and a product comprising the same it's about
인간의 근골격계(musculoskeletal system)는 인간의 움직임을 가능하게 하는 체계로서, 해부학적으로는 뼈, 근육, 연골, 인대등으로 구성되어 있으며, 혈관계, 신경계 및 면역계를 통하여 인체 전체에 통합된 시스템으로서 존재한다. The human musculoskeletal system is a system that enables human movement. Anatomically, it consists of bones, muscles, cartilage, ligaments, etc., and exists as an integrated system throughout the human body through the vascular system, the nervous system and the immune system. do.
인체내 심장 등 각종 장기가 매우 중요하지만 근골격계가 없다면 지구 중력 등 물리적 힘을 극복할 수 없어서, 정상적인 작동에 필요한 구조적 체계의 형성이 불가능할 뿐 만아니라, 동물의 특권인 자유자재의 움직임과 이동이 불가능하다. 따라서, 근골격계의 건강은 인간이 독립적인 생활을 가능하게 하는 삶의 필수 요소이다. 건강한 근골격계를 통하여 사지의 움직임의 대소, 강약을 조절하고, 유연하고, 균형잡힌 동작을 함으로써 신체 보호, 동적 기능 및 아름다움을 가능하게 해 줄 수 있다. 즉, 근골격계의 정상적 기능은 생존 및 인간의 존엄성은 물론이고 육체적 아름다움, 체육 및 예술적 차원에서 절대적으로 중요하다. Various organs in the human body, such as the heart, are very important, but without the musculoskeletal system, physical forces such as earth's gravity cannot be overcome, so it is impossible not only to form a structural system necessary for normal operation, but also to move and move freely, which is the privilege of animals. do. Therefore, the health of the musculoskeletal system is an essential element of life that enables human beings to live independently. Through a healthy musculoskeletal system, body protection, dynamic function, and beauty can be made possible by controlling the magnitude and strength of the movement of the extremities and performing flexible and balanced movements. In other words, the normal function of the musculoskeletal system is absolutely important for survival and human dignity, as well as for physical beauty, athletics and artistic dimensions.
외상에 의한 근골격계 기능 저하는 불구를 유발하는 경우를 제외하고는 많은 경우 적절한 외과수술 및 물리치료 과정에 의하여 회복된다. 그러나, 외상 후유증, 만성적 스트레스 및 노화에 의하여 근골격계를 구성하는 하나 이상의 요소가 만성적 악화과정에 돌입하게 되면 근골격계의 기능 범위가 감소하게 되고, 다시 근감소, 골밀도 저하, 말초혈류감소 등, 근골격계의 정상적 기능 구현에 필요한 구조적 요소의 악화가 일어나는 식으로 포지티브 피드백을 통하여 운동 기능이 점진적으로 악화되며, 결국 각종 위험에 노출되며 생활의 질이 크게 감소된다. In many cases, musculoskeletal dysfunction due to trauma can be recovered by appropriate surgical and physical therapy procedures, except for cases that cause disability. However, if one or more elements constituting the musculoskeletal system enter into a chronic exacerbation process due to after-traumatic trauma, chronic stress, and aging, the functional range of the musculoskeletal system is reduced, and again the normal function of the musculoskeletal system is reduced, such as decreased muscle mass, decreased bone density, decreased peripheral blood flow, etc. Motor function gradually deteriorates through positive feedback in such a way that structural elements necessary for functional implementation deteriorate, and eventually, various risks are exposed and the quality of life is greatly reduced.
외상 후유증, 특정 질병 및 노화 등으로 인하여 만성적으로 악화되는 운동 기능을 개선하기 위한 기존 접근법으로는 운동요법, 식이요법, 약물요법 등이 있지만, 어떠한 방법도 효율성, 경제성, 및 부작용 대비 효과 측면에서 만족할 만한 해법을 제시하지 못하고 있다. 이는 저하된 운동기능을 효율적으로 회복하기 위해서는 근골격계의 원활한 기능에 필수적으로 연관된 근육량, 골밀도, 혈관계, 신경계 및 면역계에 대한 총체적인 회복이 필요하지만, 마땅히 이러한 차원의 해결책이 없기 때문이다. Existing approaches for improving motor function that are chronically aggravated by traumatic aftereffects, certain diseases, and aging include exercise therapy, diet therapy, and drug therapy, but none of these methods are satisfactory in terms of efficiency, economy, and side effects vs. effects. It doesn't come up with a decent solution. This is because, in order to efficiently restore the reduced motor function, it is necessary to recover the muscle mass, bone density, vascular system, nervous system and immune system, which are essential for the smooth functioning of the musculoskeletal system, but there is no solution in this dimension.
이에 본 발명자들은 근골격계 기능의 회복을 통하여 운동기능을 개선하는 방법에 있어서 보다 통합적인 접근 방식의 필요성을 자각하여 도 1과 같은 근골격계 기능과 연동된 운동기능 개선 모델을 연구하였다. 도 1에 의하면 직립 보행능력을 포함한 인체의 원활한 운동기능을 위해 근골격계가 갖추어야할 필수 물리적 요소를 근골조직의 강도, 유연성 및 균형 감각의 세가지로 분석하였다. 이러한 세가지 요소 중 어느 하나라도 악화될 경우, 다른 요소에 악영향을 끼치는 방식으로 근골격계의 기능이 점진적으로 저하되어 운동기능이 빠르게 쇠퇴할 수 있다. 따라서 운동기능의 효율적인 회복을 위해서는 이 세가지 요소가 선순환적으로 개선될 수 있는 방법이 필요하다. 본 발명자들은 이 세가지 요소를 악화시키는 생리적 요소들을 면밀히 분석한 결과, 이 세가지 요소와의 직접적인 인과 관계가 가장 큰 요인으로서 신경전달기능 저하, 과도한 면역 및 혈행 악화의 3가지 요인과, 이 3가지 요인을 지속시키고 증폭시키는데 기여하는 보다 근원적인 요인인 세포스트레스 (Cellular Stress)를 도출하였다. 이 4가지 (1+3) 요인을 편리하고 안전한 방식으로 극복하는데 적합한 식용 가능한 조성물 및 그 섭취 방법의 개발이 필요하다는 결론에 도달하였다(도 2).Accordingly, the present inventors recognized the need for a more integrated approach in a method of improving motor function through recovery of musculoskeletal function, and studied a motor function improvement model linked to musculoskeletal function as shown in FIG. 1 . According to FIG. 1, essential physical elements that the musculoskeletal system must have for smooth movement functions of the human body, including the ability to walk upright, were analyzed into three categories: strength, flexibility, and sense of balance of musculoskeletal tissue. When any one of these three factors worsens, the function of the musculoskeletal system gradually deteriorates in a way that adversely affects the other factors, resulting in a rapid decline in motor function. Therefore, for the efficient recovery of motor function, a method that can improve these three factors in a virtuous cycle is required. As a result of a detailed analysis of the physiological factors that aggravate these three factors, the present inventors found that the direct causal relationship with these three factors is the largest factor, including the three factors of decreased neurotransmission function, excessive immunity and poor blood circulation, and these three factors. Cellular stress, a more fundamental factor that contributes to sustaining and amplifying It has been concluded that there is a need for the development of an edible composition suitable for overcoming these four (1+3) factors in a convenient and safe manner and a method for ingestion thereof (Fig. 2).
이에 따라 본 발명자들은 누구나 안심하고 손쉽게 섭취함으로써 근골격계에 대한 총체적 개선 효과를 발휘함으로써 인간의 특히 60세 이상 노인의 운동기능 개선 효과를 기대할 수 있는 조성물 및 제품을 제공하고자 한다.Accordingly, the present inventors intend to provide a composition and product that can be expected to improve the motor function of humans, especially those aged 60 years or older, by exerting an overall improvement effect on the musculoskeletal system by easily ingesting it with confidence.
상기의 목적을 달성하기 위해 본 발명은 플로로탄닌 화합물을 유효성분으로 포함하는 운동 기능 증진 또는 개선용 조성물을 제공한다. In order to achieve the above object, the present invention provides a composition for enhancing or improving exercise function comprising a phlorotannin compound as an active ingredient.
본 발명은 근골조직, 유연성 및 평형감각 중 하나 이상을 개선하여 운동 기능을 증진시키거나 개선하는 조성물을 제공한다. The present invention provides a composition for enhancing or improving motor function by improving at least one of musculoskeletal tissue, flexibility, and sense of balance.
본 발명은 근육량 및 골밀도 중 하나 이상을 개선하여 운동 기능을 증진시키거나 개선하는 조성물을 제공한다.The present invention provides a composition for enhancing or improving athletic function by improving at least one of muscle mass and bone density.
또한, 본 발명은 상기 조성물을 포함하는 운동 기능 증진 또는 개선용 제품을 제공한다.In addition, the present invention provides a product for enhancing or improving exercise function comprising the composition.
본 발명의 플로로탄닌을 유효성분으로 함유한 조성물 및 제품은 천연유래 소재로서 안전하며 사용이 간편하고, 미량 사용으로 근골격계의 원활한 기능에 필수적인 3가지 측면인 근골조직, 유연성 및 균형감각의 개선을 통해 운동기능을 증진시키고 개선하는 효과가 있다. 본 발명의 플로로탄닌을 유효성분으로 함유한 조성물 및 제품은 특히 근육량 및/또는 골밀도를 개선시키는 효과가 있다.The composition and product containing phlorotannin as an active ingredient of the present invention are safe and easy to use as a natural material, and improve the musculoskeletal tissue, flexibility and sense of balance, which are three aspects essential for the smooth functioning of the musculoskeletal system, by using a small amount. It has the effect of enhancing and improving motor function. Compositions and products containing phlorotannin as an active ingredient of the present invention are particularly effective in improving muscle mass and/or bone density.
도 1은 근골격계 기능과 연동된 운동기능 개선 모델을 도시한 것이다.1 shows a model for improving motor function linked to a musculoskeletal system function.
도 2는 근골격계 기능 약화로 인한 운동기능 악화 과정 및 관련 요인들의 유기적 관계를 도시한 것이다.Figure 2 shows the organic relationship between the process of deterioration of motor function due to the weakening of the musculoskeletal system and related factors.
이하 본 발명에 대하여 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명은 플로로탄닌 화합물을 유효성분으로 포함하는 운동 기능 증진 또는 개선용 조성물을 제공한다. 본 발명은 근골격계 기능의 회복을 통하여 운동기능을 증진시키거나 개선할 수 있는 조성물을 제공한다. 본 발명은 근골격계의 원활한 기능에 필수적인 3가지 측면인 근골조직, 유연성 및 균형감각의 개선을 통해 운동기능을 증진시키고 개선시키는 조성물을 제공한다.The present invention provides a composition for enhancing or improving exercise function comprising a phlorotannin compound as an active ingredient. The present invention provides a composition capable of enhancing or improving motor function through restoration of musculoskeletal function. The present invention provides a composition that enhances and improves motor function through improvement of three aspects essential for smooth functioning of the musculoskeletal system: musculoskeletal tissue, flexibility, and sense of balance.
외상후 후유증, 근골격계의 만성적 피로, 노화와 같은 요인들로 인해 근골격계를 구성하는 조직내 세포스트레스가 임계치 이상으로 증가하게 되면, 근골격계의 항상성에 가장 중요한 줄기세포 (근육의 경우 Satellite cells; 뼈의 경우 Mesenchymal stem cells) 내의 Redox-sensitive transcriptional factor 인 NFkB 가 활성화 됨에 따라, 줄기세포의 정상적인 분화를 통해 손상된 조직을 교체하는데 필요한 줄기세포 주변 미세환경 (Stem cell niche/microenvironment) 이 교란된다. 이로 인하여 근골격계 조직내 산화스트레스가 증가, 근육 및 골조직의 분해속도 대비 재생속도 감소, 혈류 감소, 세포의 탈수 등이 발생하게 되어 근골격계 기능 저하 및 퇴행화의 악순환에 들어가게 된다. When the cellular stress in the tissues constituting the musculoskeletal system increases beyond a threshold due to factors such as post-traumatic sequelae, chronic fatigue of the musculoskeletal system, and aging, stem cells (Satellite cells in the case of muscle; satellite cells in the case of bone) that are most important for homeostasis of the musculoskeletal system As NFkB, a redox-sensitive transcriptional factor in mesenchymal stem cells, is activated, the stem cell niche/microenvironment required to replace damaged tissues through normal differentiation of stem cells is disturbed. As a result, oxidative stress in the musculoskeletal system increases, the regeneration rate is reduced compared to the decomposition rate of muscle and bone tissue, blood flow decreases, and dehydration of cells occurs, thereby entering a vicious cycle of deterioration and degeneration of the musculoskeletal system.
본 발명자들은 이러한 악순환을 효과적으로 끊고, 선순환을 발생시키기 위한 효과적인 방법을 모색하던 중, 근골격계 기능 저하의 악순환의 과정을, 원인제공 단계 (세포스트레스 증가)로부터, 생화학적 위험 증폭 단계 (면역활성의 과도한 증가) 및 생리학적 위험 발현 단계 (말초 혈류 저하) 및 물리적 기능 저하 발현 단계 (근육 감소, 골밀도 감소, 신경전달 기능 저하)의 4 단계로 분류하였으며, 각 단계를 모두 효과적으로 역전시키는 것을 저하된 근골격계의 기능을 회복시키기 위한 필수 요소로서 파악하였다. The present inventors effectively break this vicious circle and while seeking an effective method to generate a virtuous cycle, the process of the vicious cycle of musculoskeletal function deterioration, from the cause-providing stage (increased cellular stress), to the biochemical risk amplification stage (excessive immune activity) increase) and physiological risk (decreased peripheral blood flow) and physical function decline (muscle reduction, bone density decrease, neurotransmitter function decreased) were classified into 4 stages, and effective reversal of each stage was performed for the reduced musculoskeletal system. It was identified as an essential element to restore function.
본 발명자들은 인체에 무해한 천연 성분 중에서 이러한 효과를 갖는 성분을 모색하던 중, 다양한 구조와 활성을 갖는 플로로탄닌들을 유효성분으로 함유한 조성물이 이러한 목적을 달성할 수 있음을 발견하였다. 즉, 플로로탄닌을 유효성분으로 하는 조성물이 근골격계의 총체적 기능, 즉 운동기능을 개선시킬 수 있음을 확인하고 본 발명을 완성하였다. 특히 플로로탄닌을 유효성분으로 하는 조성물이 노인성 근 감소증을 해소할 수 있음을 확인하고 본 발명을 완성하였다.The present inventors have discovered that a composition containing phlorotannins having various structures and activities as an active ingredient can achieve this purpose while searching for a component having this effect among natural ingredients that are harmless to the human body. That is, it was confirmed that the composition containing phlorotannin as an active ingredient can improve the overall function of the musculoskeletal system, that is, the motor function, and completed the present invention. In particular, it was confirmed that the composition containing phlorotannin as an active ingredient can solve senile sarcopenia and completed the present invention.
본 발명의 조성물은 세포스트레스 저감 활성, 면역 균형 조율 활성, 혈행촉진 활성 및 신경전달 촉진 활성이 최적화된 플로로탄닌 조성물로서 운동기능의 3 요소인 근골조직, 유연성 및 균형감각을 동시에 부작용 없이 빠른 시일내에 개선 시킬 수 있다. 본 발명의 조성물은 근육량 및 골밀도 중 하나이상, 특히 근육량 및 골밀도 모두를 개선시킴으로 근골계의 기능을 개선할 수 있고 그 결과 운동 기능을 개선시킬 수 있다. 본 발명의 조성물은 특히 60세 이상의 노인의 근육량 및 골밀도를 동시에 개선하여 노인의 운동 기능을 개선시킬 수 있다.The composition of the present invention is a phlorotannin composition optimized for cellular stress reduction activity, immune balance tuning activity, blood circulation promoting activity and neurotransmission promoting activity, and simultaneously provides the three elements of motor function, musculoskeletal tissue, flexibility, and balance, without side effects. can be improved within. The composition of the present invention can improve the function of the musculoskeletal system by improving at least one of muscle mass and bone density, particularly both muscle mass and bone density, and, as a result, can improve exercise function. In particular, the composition of the present invention can improve the motor function of the elderly by simultaneously improving the muscle mass and bone density of the elderly over 60 years of age.
본 발명의 조성물은 조성물을 수용액의 형태로 특정 조건 (농도, 1회 섭취량, 섭취 시점) 으로 섭취함으로써 더욱 효과를 발휘할 수 있다.The composition of the present invention can exhibit further effects by ingesting the composition in the form of an aqueous solution under specific conditions (concentration, intake amount, time of intake).
본 발명의 근골격계 기능을 회복하여 운동 기능을 개선하는 조성물에 포함되는 플로로탄닌은 통상적인 모든 방법에 의해 얻을 수 있고 시판되는 시약을 사용하여 합성할 수도 있으며 천연물, 특히 해조류로부터 추출 및 분리하여 얻을 수도 있다.Phlorotannin included in the composition for improving motor function by restoring musculoskeletal function of the present invention can be obtained by any conventional method, can also be synthesized using commercially available reagents, and can be obtained by extraction and separation from natural products, particularly seaweed. may be
본 발명의 조성물의 유효성분인 플로로탄닌은 갈조류에서 추출할 수 있으며, 구체적으로 대황(Eisenia bicyclis), 아이세니아 아르보레아(Eisenia arborea), 아이세니아 데스마레스티오데스(Eisenia desmarestioides), 아이세니아 갈라파제니스(Eisenia galapagensis), 아이세니아 매소니(Eisenia masonii), 검둥감태(Ecklonia kurome), 감태(Ecklonia cava), 곰피(Ecklonia stolonifera), 바다대나무(Ecklonia maxima), 에클로니아 라디아타(Ecklonia radiata), 에클로니아 바이시클리스(Ecklonia bicyclis), 에클로니아 바이런시네이트(Ecklonia biruncinate), 에클로니아 부시날리스(Ecklonia buccinalis), 에클로니아 카에파에스팁스(Ecklonia caepaestipes), 에클로니아 엑사스퍼타(Ecklonia exasperta), 에클로니아 파스티기아타(Ecklonia fastigiata), 에클로니아 브레빕스(Ecklonia brevipes), 에클로니아 아라보레아(Ecklonia arborea), 에클로니아 라티폴리아(Ecklonia latifolia), 에클로니아 무라티(Ecklonia muratii), 에클로니아 라디코사(Ecklonia radicosa), 에클로니아 리타디아나(Ecklonia richardiana) 및 에클로니아 라이티(Ecklonia wrightii)로 이루어진 그룹으로부터 선택된 1종 이상으로부터 추출될 수 있다.Phlorotannin, an active ingredient of the composition of the present invention, can be extracted from brown algae, specifically rhubarb (Eisenia bicyclis), Eisenia arborea (Eisenia arborea), Eisenia desmarestioides (Eisenia desmarestioides), children Eisenia galapagensis, Eisenia masonii, Ecklonia kurome, Ecklonia cava, Ecklonia stolonifera, sea bamboo (Ecklonia maxima), Ecklonia radiata (Ecklonia radiata), Ecklonia bicyclis, Ecklonia biruncinate, Ecklonia buccinalis, Ecklonia caepaestipes, Ecklonia exas Ecklonia exasperta, Ecklonia fastigiata, Ecklonia brevipes, Ecklonia arborea, Ecklonia latifolia, Ecklonia murati Ecklonia muratii), Ecklonia radicosa, Ecklonia richardiana, and Ecklonia wrightii may be extracted from at least one selected from the group consisting of.
본 발명의 조성물의 유효성분인 플로로탄닌 화합물은 플로로탄닌 화합물 중 특히 하기 화학식 1-12의 엑콜계 화합물들이 바람직하다. 엑콜계 화합물들은 분자량이 비교적 작으며, 3개 또는 5개의 축합환 구조(fused ring system)을 가진 것으로 단단하면서 납작한 평면구조와 함께 디-히드록시페놀(di-hydroxyphenyl) 또는 트리-히드록시페놀(tri-hydroxyphenyl) 기의 자유로운 회전을 통한 다양한 conformation을 가질 수 있어서 인체의 다양한 조직에서 화합물별 특정 구조에 따라 다양한 생리활성을 나타낼 수 있다. As the active ingredient of the composition of the present invention, the phlorotannin compound is preferably an Ekcol-based compound represented by the following Chemical Formula 1-12 among phlorotannin compounds. Ekkol-based compounds have a relatively small molecular weight, and have a three or five fused ring system, with a hard and flat planar structure, and di-hydroxyphenyl or tri-hydroxyphenol ( Because it can have various conformations through free rotation of tri-hydroxyphenyl) groups, various physiological activities can be exhibited according to the specific structure of each compound in various tissues of the human body.
본 발명의 조성물의 유효성분인 플로로탄닌 화합물은 보다 바람직하게는 하기 화학식 1 내지 12 의 화합물 중 선택되는 1종 이상의 화합물일 수 있다.The phlorotannin compound, which is an active ingredient of the composition of the present invention, may more preferably be at least one compound selected from compounds of the following Chemical Formulas 1 to 12.
[화학식 1][Formula 1]
Figure PCTKR2021000645-appb-I000001
Figure PCTKR2021000645-appb-I000001
[화학식 2][Formula 2]
Figure PCTKR2021000645-appb-I000002
Figure PCTKR2021000645-appb-I000002
[화학식 3][Formula 3]
Figure PCTKR2021000645-appb-I000003
Figure PCTKR2021000645-appb-I000003
[화학식 4][Formula 4]
Figure PCTKR2021000645-appb-I000004
Figure PCTKR2021000645-appb-I000004
[화학식 5][Formula 5]
Figure PCTKR2021000645-appb-I000005
Figure PCTKR2021000645-appb-I000005
[화학식 6][Formula 6]
Figure PCTKR2021000645-appb-I000006
Figure PCTKR2021000645-appb-I000006
[화학식 7][Formula 7]
Figure PCTKR2021000645-appb-I000007
Figure PCTKR2021000645-appb-I000007
[화학식 8][Formula 8]
Figure PCTKR2021000645-appb-I000008
Figure PCTKR2021000645-appb-I000008
[화학식 9][Formula 9]
Figure PCTKR2021000645-appb-I000009
Figure PCTKR2021000645-appb-I000009
[화학식 10][Formula 10]
Figure PCTKR2021000645-appb-I000010
Figure PCTKR2021000645-appb-I000010
[화학식 11][Formula 11]
Figure PCTKR2021000645-appb-I000011
Figure PCTKR2021000645-appb-I000011
[화학식 12][Formula 12]
Figure PCTKR2021000645-appb-I000012
Figure PCTKR2021000645-appb-I000012
본 발명의 운동 기능 개선용 조성물은 상기 플로로탄닌 화합물을 0.001-100 중량%, 바람직하게는 0.1-100중량% 포함할 수 있다. 본 발명의 운동 기능 개선용 조성물은 물을 0-99.999중량% 포함할 수 있다.The composition for improving exercise function of the present invention may contain 0.001-100% by weight of the phlorotannin compound, preferably 0.1-100% by weight. The composition for improving exercise function of the present invention may contain 0-99.999% by weight of water.
본 발명의 조성물은 특히 세포스트레스 저감 활성이 우수한 화학식 7, 및 면역균형촉진 활성 및 혈행촉진 활성이 우수한 화학식 1 내지 6으로부터 선택되는 1종 이상의 플로로탄닌, 및 신경전달촉진 활성이 우수한 화학식 8 내지 12로부터 선택되는 1종 이상의 플로로탄닌이 조합될 때 더욱 우수한 효과를 발휘할 수 있다.In particular, the composition of the present invention contains at least one phlorotannin selected from Chemical Formula 7, which is excellent in cell stress reducing activity, and Chemical Formula 1 to 6, which has excellent immune balance promoting activity and blood circulation promoting activity, and Chemical Formula 8 to excellent neurotransmission promoting activity. When one or more phlorotannins selected from 12 are combined, a more excellent effect may be exhibited.
본 발명의 운동 기능 개선용 조성물은 바람직하게는 화학식 7, 및 화학식 1 내지 6의 플로로탄닌으로부터 선택되는 1종 이상의 플로로탄닌, 및 화학식 8 내지 12의 플로로탄닌으로부터 선택되는 1종 이상의 플로로탄닌을 중량비로 각각 5~50%, 15~65% 및 10~50% 포함하는 경우 근골격계 기능 회복에 필요한 세포스트레스 저감 활성, 면역균형촉진 활성, 혈행촉진 활성 및 신경전달촉진 활성이 동시에 또한 시너지적으로 그 효과를 발휘하여 결과적으로 운동 기능의 개선 효과를 가져올 수 있다.The composition for improving motor function of the present invention is preferably at least one phlorotannin selected from phlorotannins of Chemical Formula 7 and Chemical Formulas 1 to 6, and at least one phlorotannin selected from Chemical Formulas 8 to 12 phlorotannin. When rotannin is contained in 5-50%, 15-65%, and 10-50% by weight, respectively, cellular stress reduction activity, immune balance promoting activity, blood circulation promoting activity, and neurotransmission promoting activity necessary for recovery of musculoskeletal function are simultaneously and synergistic. As a result, it can exert its effect in a negative way, resulting in the improvement of motor function.
본 발명의 운동기능 개선용 조성물은 전체 중량에 대하여 화학식 2의 플로로탄닌 15~40중량%, 화학식 7의 플로로탄닌 5~50중량% 및 화학식 10의 플로로탄닌 10~50중량% 포함하는 경우 근골격계 기능 회복에 필요한 세포스트레스 저감 활성, 면역균형촉진 및 혈행촉진 활성 및 신경전달촉진 활성이 동시에 또한 시너지적으로 그 효과를 발휘하여 결과적으로 운동 기능의 개선 효과를 가져올 수 있다.The composition for improving exercise function of the present invention comprises 15 to 40% by weight of phlorotannin of Formula 2, 5 to 50% by weight of phlorotannin of Formula 7, and 10 to 50% by weight of phlorotannin of Formula 10 with respect to the total weight In this case, the cellular stress reduction activity, immune balance promotion and blood circulation promoting activity, and neurotransmission promoting activity required for the recovery of musculoskeletal function simultaneously and synergistically exert their effects, resulting in improvement of motor function.
본발명의 운동기능 개선용 조성물은 전체 중량에 대하여 화학식 1의 플로로탄닌 1 ~ 35중량%, 화학식 2의 플로로탄닌 1 ~ 50중량%, 화학식 3의 플로로탄닌 1 ~ 50중량%, 화학식 4의 플로로탄닌 0.5 ~ 10중량%, 화학식 5의 플로로탄닌 0.5 ~ 10중량%, 화학식 6의 플로로탄닌 0.5 ~ 10중량%, 화학식 7의 플로로탄닌 15 ~ 65중량%, 화학식 8의 플로로탄닌 0.1 ~ 20중량%, 화학식 9의 플로로탄닌 0.1 ~ 20중량%, 화학식 10의 플로로탄닌 1 ~ 30중량%, 화학식 11의 플로로탄닌 1 ~ 20중량% 및 화학식 12의 플로로탄닌 0.1 ~ 20중량%를 포함하는 경우 운동 기능의 개선 효과를 가져올 수 있다.The composition for improving exercise function of the present invention is 1 to 35% by weight of phlorotannin of Formula 1, 1 to 50% by weight of phlorotannin of Formula 2, 1 to 50% by weight of phlorotannin of Formula 3, with respect to the total weight of the composition for improving exercise function of the present invention Phlorotannin of 0.5 to 10% by weight of 4, phlorotannin of 0.5 to 10% by weight of Formula 5, phlorotannin of 0.5 to 10% by weight of Formula 6, phlorotannin of 15 to 65% by weight of Formula 7, Formula 8 Phlorotannin 0.1 to 20% by weight, phlorotannin 0.1 to 20% by weight of Formula 9, phlorotannin 1 to 30% by weight of Formula 10, phlorotannin 1 to 20% by weight of Formula 11, and fluoro of Formula 12 If 0.1 to 20% by weight of tannins are included, it may bring about an effect of improving exercise function.
본 발명의 조성물은 수용액으로 섭취하는 경우 그 효과가 우수할 수 있다. 특히 본 발명의 조성물은 플로로탄닌을 0.1~100 ppm 농도, 바람직하게는 1-100ppm 농도의 20~50℃의 수용액으로 1회 10 내지 200mL, 바람직하게는 50~200mL 섭취하는 경우 식도, 소장, 대장 등 위장관 전체에서의 흡수가 촉진되어 근골격계 기능을 개선하여 운동 기능을 개선할 수 있다. When the composition of the present invention is ingested as an aqueous solution, the effect may be excellent. In particular, the composition of the present invention contains phlorotannin at a concentration of 0.1 to 100 ppm, preferably 10 to 200 mL, preferably 50 to 200 mL, in an aqueous solution of 1-100 ppm at a concentration of 20 to 50 ° C. When ingested, the esophagus, small intestine, Absorption in the entire gastrointestinal tract, including the large intestine, is accelerated, improving the musculoskeletal system and improving motor function.
본 발명의 운동 기능 개선용 조성물은 공복시나 식음료와 함께 및 식후에 섭취할 수 있으나, 공복시 특히 아침기상 직후, 저녁 취침직전 등 인체 휴식기에 섭취함으로써 더욱 효과적이다.The composition for improving exercise function of the present invention can be consumed on an empty stomach or with food and beverages and after a meal, but it is more effective when taken on an empty stomach, particularly right after waking up in the morning, or during a rest period of the human body, such as just before going to bed in the evening.
본 발명은 상기 운동 기능 개선용 조성물을 포함하는 운동 기능 증진 또는 개선용 제품을 제공한다.The present invention provides a product for enhancing or improving exercise function comprising the composition for improving exercise function.
상기 플로로탄닌을 포함하는 운동 기능 개선용 제품은 액상, 분말, 발포정, 단백질바(bar), 캅셀 등의 형태로 제품화 될 수 있으나 이에 한정되는 것은 아니다. 특히 본 발명의 플로로탄닌을 포함하는 운동 기능 개선용 제품은 액상 형태로 제공되어 섭취되거나, 분말 또는 발포정의 형태로 제공되어 물에 용해시킨 형태로 섭취되는 경우 위장관에서의 흡수가 촉진되어 근골격계 기능을 개선하여 결과적으로 운동 기능을 개선할 수 있다. 또한 본 발명의 플로로탄닌을 포함하는 운동 기능 개선용 제품이 단백질바, 캅셀 등의 형태로 제공되는 경우 충분한 물과 함께 섭취하여 흡수를 촉진하는 것이 바람직하다.The product for improving exercise function containing the phlorotannin may be commercialized in the form of a liquid, powder, effervescent tablet, protein bar, capsule, etc., but is not limited thereto. In particular, when the product for improving exercise function containing phlorotannin of the present invention is provided in a liquid form and ingested, or in the form of a powder or effervescent tablet dissolved in water, absorption in the gastrointestinal tract is promoted and musculoskeletal function is provided. can improve motor function as a result. In addition, when the product for improving exercise function containing phlorotannin of the present invention is provided in the form of a protein bar or capsule, it is preferable to consume it with sufficient water to promote absorption.
본 발명의 제품은 플로로탄닌을 0.1~100 ppm 농도, 바람직하게는 1-100ppm 농도의 20~50℃의 수용액으로 1회 10 내지 200mL, 바람직하게는 50~200mL 섭취하는 경우 식도, 소장, 대장 등 위장관 전체에서의 흡수가 촉진되어 근골격계 기능을 개선하여 운동 기능을 개선할 수 있다.The product of the present invention contains phlorotannin at a concentration of 0.1 to 100 ppm, preferably at a concentration of 1-100 ppm, in an aqueous solution at 20-50 ° C. 10 to 200 mL, preferably 50 to 200 mL, when ingested at a time, esophagus, small intestine, large intestine Absorption in the entire gastrointestinal tract is promoted, thereby improving the musculoskeletal system function, thereby improving motor function.
본 발명의 제품은 플로로탄닌을 포함하는 운동기능 개선용 조성물과 함께 보조성분으로 단백질, 글리코시달 사포닌, 이노시톨, 글루코마난, 덱스트린, 아미노산, 무기염류 및 비타민으로 이루어진 군에서 선택되는 1종 이상을 더 포함하는 경우 근골겨계 기능을 개선할할 수 있다.The product of the present invention contains at least one selected from the group consisting of protein, glycosidal saponin, inositol, glucomanan, dextrin, amino acids, inorganic salts and vitamins as an auxiliary component together with a composition for improving exercise function containing phlorotannin. If it is further included, it is possible to improve the musculoskeletal system function.
본 발명의 운동 기능 개선용 조성물 및 제품에 포함되는 플로로탄닌의 1일 사용량은 50kg 성인 기준 0.1~100 mg 정도가 바람직하나 사용량이 상기의 범위에 한정되는 것은 아니다. The daily usage of phlorotannin contained in the composition and product for improving exercise function of the present invention is preferably about 0.1 to 100 mg based on a 50 kg adult, but the usage is not limited to the above range.
본 발명의 운동 기능 개선용 제품은 플로로탄닌 화합물이 1~100ppm 포함된 액상의 형태로 1일 10 ~2000mL, 바람직하게는 50-500mL 섭취하는 경우 근육량, 골밀도, 유연성 및 균형감각을 개선할 수 있다.The product for improving motor function of the present invention can improve muscle mass, bone density, flexibility and sense of balance when ingested in a liquid form containing 1 to 100 ppm of phlorotannin compound, 10 to 2000 mL, preferably 50 to 500 mL per day. there is.
이하에서 실시예를 통하여 본 발명을 보다 상세히 설명한다. 그러나 하기의 실시예는 본 발명을 더욱 구체적으로 설명하기 위한 것으로서, 본 발명의 범위가 하기의 실시예에 의하여 한정되는 것은 아니다. 하기의 실시예는 본 발명의 범위 내에서 당업자에 의해 적절히 수정, 변경될 수 있다.Hereinafter, the present invention will be described in more detail through examples. However, the following examples are for explaining the present invention in more detail, and the scope of the present invention is not limited by the following examples. The following examples can be appropriately modified and changed by those skilled in the art within the scope of the present invention.
실시예 1. 플로로탄닌 화합물 제조Example 1. Preparation of phlorotannin compound
본 발명의 플로로탄닌을 유효성분으로 하는 조성물을 제조하기 위하여 제주도 근해에서 수집된 갈조류인 감태(Ecklonia cava)로부터 하기의 방법으로 추출하였다.In order to prepare a composition containing phlorotannin as an active ingredient of the present invention, it was extracted from Ecklonia cava , a brown algae collected near Jeju Island, by the following method.
감태를 증류수로 세척하여 이물질을 제거하고 음지에서 건조한 후, 이를 파쇄하였다. 추출용기에 상기 감태 5kg을 담았으며, 상기 감태 중량 대비 20배의 30 중량% 주정 수용액을 첨가하고, 75 내지 80℃에서 4시간 동안 환류 추출하여 추출액을 얻었다. 상기 추출액을 10㎛의 여과망에 여과하고, 여과된 추출물을 55℃의 수욕에서 감압 농축하여 1차 추출농축액을 얻었다. 상기 1차 추출농축액을 70torr의 압력으로 90℃에서 8시간이상 진공건조기로 건조한 후, 분쇄하여 1차 추출물을 1700g 얻었다. Ecklonia cava was washed with distilled water to remove foreign substances, dried in the shade, and crushed. Put 5 kg of Ecklonia cava in an extraction container, and 20 times the weight of Ecklonia cava, 30% by weight aqueous solution of alcohol was added, and extracted under reflux at 75 to 80° C. for 4 hours to obtain an extract. The extract was filtered through a 10 μm filter, and the filtered extract was concentrated under reduced pressure in a water bath at 55° C. to obtain a primary extract concentrate. The primary extract concentrate was dried in a vacuum dryer at 90° C. for at least 8 hours at a pressure of 70 torr, and then pulverized to obtain 1700 g of the primary extract.
상기 1차 추출물을 50℃의 온수에 용해한 뒤, 흡착수지에 흡착시킨 후, 물로 세척하고 주정으로 용출하여 플로로탄닌 용출액을 얻었다. 상기 용출액을 1㎛의 여과망에 여과하고, 여과된 추출물을 55℃의 수욕에서 감압 농축하여 2차 추출농축액을 얻었다. 상기 2차 추출농축액을 70 torr의 압력으로 90℃에서 8시간이상 진공건조기로 건조한 후, 분쇄하여 2차 추출물을 300g 을 얻었다. The primary extract was dissolved in hot water at 50° C., adsorbed on an adsorption resin, washed with water, and eluted with alcohol to obtain a phlorotannin eluate. The eluate was filtered through a 1 μm filter, and the filtered extract was concentrated under reduced pressure in a water bath at 55° C. to obtain a secondary extract concentrate. The secondary extract concentrate was dried in a vacuum dryer at 90° C. for at least 8 hours at a pressure of 70 torr, and then pulverized to obtain 300 g of the secondary extract.
상기 2차 추출물을 주정에 용해하고 필터에이드(규조토 또는 벤토나이트)를 첨가 및 필터하여 용출액을 얻었다. 상기 용출액을 1㎛의 여과망에 여과하고, 여과된 용출물을 55℃의 수욕에서 감압 농축하여 농축액을 얻었다. 상기 농축액을 70 torr의 압력으로 90℃에서 8시간이상 진공건조기로 건조한 후, 분쇄하여 3차 추출물을 190g 얻었다. The secondary extract was dissolved in alcohol, and filter aid (diatomaceous earth or bentonite) was added and filtered to obtain an eluate. The eluate was filtered through a 1 µm filter, and the filtered eluate was concentrated under reduced pressure in a water bath at 55°C to obtain a concentrate. The concentrate was dried in a vacuum dryer at 90° C. for at least 8 hours at a pressure of 70 torr, and then pulverized to obtain 190 g of a tertiary extract.
상기에서 얻은 3차 추출물을 액체 크로마토그래피에 로딩(loading)하여 화합물 분리를 진행하여 플로로탄닌 분획 I, II 및 분획 III를 각각 104g, 18g 및 33g을 얻었다. 이때 얻어진 세개의 분획을 각각 60% 메탄올에 용해시킨 후 0.2㎛ 막여과지로 여과하여 고속 액체 크로마토그래피에 로딩(loading)하였다. 고속 액체 크로마토그래피에서, 컬럼은 HP ODS Hypersil, 용매는 증류수와 메탄올을 사용하였으며, 용매의 공급은 1.0㎖/분의 유속으로 메탄올 15%에서 70%까지 30분간에 걸쳐 선형구배(linear gradient)를 걸어, 화학식 1 내지 12의 화합물을 얻고 이를 NMR 등으로 동정하였다. 분리한 화합물의 건조 중량을 하기 표 1 에 나타내었다.The tertiary extract obtained above was loaded on liquid chromatography to proceed with compound separation to obtain 104 g, 18 g and 33 g of phlorotannin fractions I, II and III, respectively. At this time, each of the three fractions obtained was dissolved in 60% methanol, filtered with 0.2 μm membrane filter paper, and loaded into high performance liquid chromatography. In high-performance liquid chromatography, the column was HP ODS Hypersil, the solvent was distilled water and methanol, and the solvent was supplied at a flow rate of 1.0 ml/min. From 15% to 70% of methanol, a linear gradient was performed over 30 minutes. Then, compounds of Formulas 1 to 12 were obtained, which were identified by NMR or the like. The dry weight of the separated compound is shown in Table 1 below.
  화학식 1Formula 1 화학식 2Formula 2 화학식 3Formula 3 화학식 4Formula 4 화학식 5Formula 5 화학식 6Formula 6 화학식 7Formula 7 화학식 8Formula 8 화학식 9Formula 9 화학식 10Formula 10 화학식 11Formula 11 화학식 12Formula 12
중량weight 20.020.0 26.126.1 17.917.9 14.814.8 9.09.0 8.48.4 13.913.9 4.44.4 4.74.7 14.814.8 3.73.7 3.23.2
실시예 2. 플로로탄닌 화합물 포함 조성물의 제조Example 2. Preparation of a composition comprising a phlorotannin compound
화학식 1~12의 화합물에 대한 세포스트레스저감 활성, 면역균형조율 활성, 혈행촉진 활성 및 신경전달촉진 활성을 아래와 같이 측정하였다. Cell stress reducing activity, immune balance tuning activity, blood circulation promoting activity and neurotransmission promoting activity for the compounds of Formulas 1 to 12 were measured as follows.
세포스트레스저감 활성: 세포 차원에서의 스트레스를 지칭하는 ER Stress 에 끼치는 효과를 측정하였다. 10μM 농도의 화학식 1~12의 화합물로 각각 1시간 동안 처리한 SH-SY5Y 세포주에, ER stress 에 의한 세포사멸을 일으키는 것으로 잘 알려진 Thapsigargin 1000nM 을 더하고 24시간 동안 처리한 후 MTT (3-(4, 5- dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 용액 처리 (2h, 37℃, 5% CO2)를 하여 540nm에서 formazan 생성을 측정하여 각 화합물 별 세포 사멸이 완화된 정도를 측정하였다. Cell stress-reducing activity: The effect on ER Stress, which refers to stress at the cellular level, was measured. To the SH-SY5Y cell line treated with the compounds of Formulas 1 to 12 at a concentration of 10 μM for 1 hour, 1000 nM of Thapsigargin, which is well known to cause apoptosis by ER stress, was added and treated for 24 hours, followed by MTT (3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) solution treatment (2h, 37℃, 5% CO2) and formazan production was measured at 540nm to measure the degree of apoptosis relief for each compound.
면역균형조율 활성: 노화는 만성염증을 수반하여 면역균형을 깨뜨린다. 생화학적으로는 염증유발성 전사인자인 NFkB가 만성적으로 활성화되어 근골조직의 퇴행화를 유도하게 되므로, NFkB 의 활성화도를 측정하였다. RAW 264.7 대식세포주에 NFkB-Luc reporter plasmid (Clontech, Shiga, Japan) 를 transfection 시킨후 화학식 1-12의 화합물 각 10 μM 를 1시간 동안 처리한후, LPS (1μg/mL)을 처리하여 24시간 후에 luciferase 활성을 측정하여 NFkB 활성화도를 측정하였다.Immune balancing activity: Aging is accompanied by chronic inflammation and disrupts the immune balance. Biochemically, since NFkB, an inflammation-inducing transcription factor, is chronically activated and induces degeneration of musculoskeletal tissue, the degree of activation of NFkB was measured. RAW 264.7 macrophage cell line was transfected with NFkB-Luc reporter plasmid (Clontech, Shiga, Japan), treated with 10 μM of each compound of Formula 1-12 for 1 hour, and then treated with LPS (1 μg/mL) for 24 hours. NFkB activation was measured by measuring luciferase activity.
혈행촉진활성: 노화는 혈액의 과응고 경향을 초래하여 생리학적으로 혈행을 저하시킴으로써 근골 조직의 항상성을 저하시키고 퇴행화에 기여하게 된다. 따라서 혈액 응고속도의 지표중 대표적인 aPTT 를 측정하였다. 구연산 처리된 정상적인 인체 혈장 (90 μL)에 100 μM 농도의 화학식 1~12의 화합물 각 10μL 를 혼합한 후 37℃에서 1분간 방치하였다. 이어서 aPTT assay reagent (Fisher Diagnostics, USA) 100μL를 추가한 후 37℃에서 1분간 방치한 후 20mM CaCl2 (100μL)를 더하여 응고되는데 걸리는 시간(초)을 측정하였다. Blood circulation promoting activity: Aging causes the tendency of blood to overcoagulate and physiologically decreases blood circulation, thereby reducing homeostasis of musculoskeletal tissue and contributing to degeneration. Therefore, aPTT, a representative index of blood coagulation rate, was measured. After mixing 10 μL of each of the compounds of Formulas 1 to 12 at a concentration of 100 μM in citric acid-treated normal human plasma (90 μL), the mixture was left at 37° C. for 1 minute. Then, after adding 100 μL of aPTT assay reagent (Fisher Diagnostics, USA), it was left at 37° C. for 1 minute, and then 20 mM CaCl 2 (100 μL) was added to measure the time (seconds) required for coagulation.
신경전달촉진활성: 근골조직의 운동작용을 촉발시키기 위해서는 신경전달물질인 아세틸콜린 (Acetylcholine)이 필요하며, 노화조직의 신경에서는 아세틸콜린이 부족한 현상이 나타난다. 따라서 아세틸콜린을 분해하는 아세틸콜린 가수분해 효소 (AChE)에 대한 저해 활성을 측정하였다. DTNB (5,5'-dithiobis(2-nitrobenzoic acid) 용액 (900μL of 5.55mM DTNB in 50mM potassium phosphate buffer, pH 7.4)에 ATCh (Acetylthiocholine chloride) 용액 (2mM ATCh, 25μL) 및 1mM 농도의 화학식 1~12의 화합물 각 20μL를 혼합한 후, AChE (0.005 unit in 75μL buffer) 를 더하여 효소 반응을 일으키고 412nm 에서 흡광도 변화를 60초 동안 측정하여 AChE 에 대한 저해 활성을 측정하였다. Neurotransmission-promoting activity: Acetylcholine, a neurotransmitter, is required to trigger the movement of musculoskeletal tissue, and acetylcholine is insufficient in the nerves of aging tissues. Therefore, the inhibitory activity on acetylcholine hydrolase (AChE) that degrades acetylcholine was measured. In DTNB (5,5'-dithiobis(2-nitrobenzoic acid) solution (900μL of 5.55mM DTNB in 50mM potassium phosphate buffer, pH 7.4), ATCh (Acetylthiocholine chloride) solution (2mM ATCh, 25μL) and 1mM concentration of Formula 1~ After mixing 20 μL of each compound of 12, AChE (0.005 unit in 75 μL buffer) was added to cause an enzymatic reaction, and the change in absorbance at 412 nm was measured for 60 seconds to measure inhibitory activity on AChE.
각 항목에 대하여 측정된 활성에 있어서 가장 낮은 정도에서 높은 정도를 1 에서 10까지의 스케일로 표준화하여 표 2에 나타내었다. 화학식 1~6은 면역균형조율 활성 및 혈행촉진 활성에서, 화학식 7은 세포스트레스저감 활성에서, 화학식 8~12는 신경전달 촉진활성에서 각각 높은 스코어를 나타내었으며, 이 결과를 토대로 화학식1~12의 화합물을 다양한 비율로 혼합하여 조성물 1 내지 9를 제조하였다 (표 3). In Table 2, the measured activity for each item was standardized from the lowest to the highest on a scale of 1 to 10. Chemical formulas 1 to 6 showed high scores in immunobalancing activity and blood circulation promoting activity, Chemical formula 7 in cellular stress reducing activity, and Chemical formula 8 to 12 in neurotransmission promoting activity, respectively. Compositions 1 to 9 were prepared by mixing the compounds in various ratios (Table 3).
  세포스트레스 저감 활성Cell stress reduction activity 면역균형조율 활성Immune balancing activity 혈행촉진 활성Blood circulation promotion activity 신경전달 촉진 활성Neurotransmission-promoting activity
화학식 1Formula 1 22 88 1010 1One
화학식 2Formula 2 44 1010 99 1One
화학식 3Formula 3 44 1010 99 1One
화학식 4Formula 4 55 1010 77 1One
화학식 5Formula 5 44 88 77 1One
화학식 6Formula 6 33 77 88 1One
화학식 7Formula 7 1010 55 55 55
화학식 8Formula 8 44 55 33 77
화학식 9Formula 9 44 33 33 99
화학식 10Formula 10 55 22 33 1010
화학식 11Formula 11 22 1One 33 88
화학식 12Formula 12 33 1One 33 88
  조성물1composition 1 조성물2composition 2 조성물3composition 3 조성물4composition 4 조성물5composition 5 조성물6composition 6 조성물7composition 7 조성물8composition 8 조성물9composition 9
화학식 1Formula 1       3030 2020     1010 1515
화학식 2Formula 2   5050   2020 1515   3030 1010 1515
화학식 3Formula 3   5050     1010     1010 1010
화학식 4Formula 4         55     55  
화학식 5Formula 5               55  
화학식 6Formula 6               55  
화학식 7Formula 7 100100     5050   5050 4040 2525 3030
화학식 8Formula 8           1010   55  
화학식 9Formula 9           1010   55  
화학식 10Formula 10     100100   3030 2020 3030 1010 3030
화학식 11Formula 11         2020 1010   55  
화학식 12Formula 12               55  
합계Sum 100100 100100 100100 100100 100100 100100 100100 100100 100100
실시예 3. 플로로탄닌이 포함된 제품의 제조Example 3. Preparation of products containing phlorotannin
제조된 각 조성물과 덱스트린을 1:99의 중량비로 혼합하여 조성물 1~9 가 각각 1% 함유된 제품예 1~9를 제조하였다. 모든 조성물이 특별한 맛이 없으나 연한 노랑의 색을 띄므로 덱스트린에 카라멜 색소를 미량 추가하여 걷보기와 맛이 조성물과 구별되지 않는 플라시보 제품 (비교 제품예 1)을 제조하였다.Each of the prepared compositions and dextrin were mixed in a weight ratio of 1:99 to prepare Product Examples 1 to 9 each containing 1% of the compositions 1 to 9. Since all the compositions had no particular taste, but had a pale yellow color, a small amount of caramel pigment was added to the dextrin to prepare a placebo product (Comparative Product Example 1) in which walking and taste were indistinguishable from the composition.
실험예 1. 노인의 운동 기능 개선 효과Experimental Example 1. Effect of improving motor function in the elderly
65세 이상 노인 100명을 대상으로 제품예 및 비교예 제품이 용해된 음료를 4주간 매일 500mL 씩 섭취하도록 하고, 섭취 전 후의 골밀도 (T-Score), 근육량(%FFMI: Fat-Free Muscle Index), 하지 유연성(좌전굴) 및 균형능력(외발서기) 를 측정하였다. 100 seniors 65 years of age or older were instructed to consume 500mL of a beverage containing product examples and comparative examples daily for 4 weeks, and bone density (T-Score) and muscle mass (%FFMI: Fat-Free Muscle Index) before and after intake. , lower extremity flexibility (left flexion) and balance ability (unilateral standing) were measured.
대상자들의 골밀도(T-score), 근육량(%FFMI)의 변화를 알아보기 위해 신장 및 체중을 측정한 후, 이중에너지 방사선 측정법(DEXA: Dual Energy X-ray Absorptiometry)을 이용하여 측정하였다. 장비는 Lunar prodigy(GE medical systems, Waukesha, Wisconsin, U.S.A)를 이용하였다. After measuring the height and weight to determine the changes in bone density (T-score) and muscle mass (%FFMI) of the subjects, it was measured using Dual Energy X-ray Absorptiometry (DEXA). As the equipment, Lunar prodigy (GE medical systems, Waukesha, Wisconsin, U.S.A) was used.
하지 유연성 (좌전굴: Sit & Reach Flexibility Test)은 다음과 같은 방법으로 측정하였다. 40 cm 높이의 측정대에 양발 끝을 5cm 정도 벌린 상태로 대고 앉아서, 측정기 (Trunk Flexion Tester) 를 최대로 밀어내도록 하였다. 상체를 흔들어 그의 반동으로 몸을 앞으로 굽히지 않도록 하였으며, 측정시 무릎이 펴져 있도록 하였다. 또한 한쪽 손 끝이 다른 손끝과 같은 선상에 있도록 하고, 상체를 앞으로 굽혔을 때 머리는 양팔 사이에 있도록 하였다. 단위는 0.1cm로 하여, 3회 측정 결과 가장 좋은 기록을 선택하였다. Lower extremity flexibility (left flexion: Sit & Reach Flexibility Test) was measured as follows. Sitting on a 40 cm high measuring table with both feet spread 5 cm apart, the Trunk Flexion Tester was pushed to the maximum. Shaking the upper body, the body was not bent forward by the recoil, and the knee was kept straight during measurement. Also, the tip of one hand was placed on the same line as the tip of the other, and when the upper body was bent forward, the head was placed between the arms. The unit was set to 0.1 cm, and the best record was selected as a result of three measurements.
균형능력을 측정하기 위해 외발서기 검사를 실시하였다. 외발서기 검사는 자세균형을 양적으로 측정 할 수 있으며, 간편하게 측정 할 수 있는 방법이다 (Rossiter-Fornoff, Wolf, Wolfson, Buchner & FICSIT Group, The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 50(6), M291 -M297 (1995)로서, 본 연구에서는 다리를 후방으로 들고 무릎 관절을 90도로 구부리게 하고, 두 눈을 뜬 채로 진행 하였으며, 든 다리의 발이 지면에 닿기 전까지의 시간을 측정하였다. 총 2회 측정하여 가장 높은 기록을 사용하였다.To measure balance ability, a uni-legged test was performed. The one-legged test can quantitatively measure postural balance and is a convenient method (Rossiter-Fornoff, Wolf, Wolfson, Buchner & FICSIT Group, The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 50 ( 6), M291 -M297 (1995), in this study, the leg was lifted backward, the knee joint was bent at 90 degrees, both eyes were open, and the time until the foot of the raised leg touched the ground was measured. A total of two measurements were taken and the highest record was used.
시험음료의 제조 및 섭취 방법: 매일 저녁, 500 mL 용량의 보온병에 제품예 1~9 또는 비교제품예 1 을 미리 지급된 플라스틱 숫가락 (700mg 용량) 한개의 양에 해당하도록 넣고, 40~50℃의 생수 500mL 을 더하여 뚜껑을 닫고 흔들어 완전히 용해시켰다. 다음날 기상 직후, 공복에 150mL 을 섭취하고, 식간에 총 200mL 을 자유롭게 섭취하고, 취침전 공복에 나머지 150mL 을 섭취하도록 하였다. 섭취시의 용액의 온도는 25~40℃ 범위내에 있었다. 결과를 하기 표 4에 나타내었다.Preparation and intake method of test drink: Every evening, put Product Examples 1 to 9 or Comparative Product Example 1 into a 500 mL thermos in the same amount as one plastic spoon (700 mg capacity) provided in advance, and put it at 40-50 ° C. 500mL of mineral water was added, the lid was closed, and completely dissolved by shaking. Immediately after waking up the next day, 150 mL was taken on an empty stomach, a total of 200 mL was freely ingested between meals, and the remaining 150 mL was taken on an empty stomach before bedtime. The temperature of the solution at the time of ingestion was in the range of 25-40 °C. The results are shown in Table 4 below.
시험 결과, 제품예 1~9 을 섭취한 경우 모두에서 비교 제품예 대비 근육량, 골밀도, 좌전굴 및 외발서기의 모든 항목에서 개선 효과를 나타냄을 확인하였다. 특히 조성물 7, 8, 9 (제품예 7, 8, 9)에서 가장 우수한 효과를 나타냄을 확인함으로써, 특정 플로로탄닌의 조합에 의하여 운동기능의 3요소인 근골조직, 유연성 및 균형감각의 개선 효과에 있어서 시너지 효과가 나타남을 확인하였다.As a result of the test, it was confirmed that in all of the cases of ingestion of Product Examples 1 to 9, the improvement effect was exhibited in all items of muscle mass, bone density, left flexion and unilateral standing compared to the comparative product example. In particular, by confirming that the compositions 7, 8, and 9 (Product Examples 7, 8, 9) show the most excellent effect, the improvement effect of musculoskeletal tissue, flexibility and balance, which are three elements of motor function, by the combination of a specific phlorotannin It was confirmed that a synergistic effect appeared in
  제품예1Product example 1 제품예2Product example 2 제품예3Product example 3 제품예4Product example 4 제품예5Product example 5 제품예6Product example 6 제품예7Product example 7 제품예8Product example 8 제품예9Product example 9
T-ScoreT-Score 3.03.0 4.04.0 2.22.2 5.95.9 8.68.6 5.25.2 15.015.0 16.116.1 14.214.2
%FFMI%FFMI 3.03.0 7.07.0 5.05.0 8.78.7 7.37.3 7.77.7 10.310.3 14.314.3 13.013.0
좌전굴 left bend 2.72.7 4.64.6 4.24.2 5.45.4 6.46.4 6.06.0 7.57.5 8.68.6 8.68.6
외발서기 one-legged clerk 6.66.6 3.73.7 11.911.9 7.37.3 17.017.0 14.114.1 25.925.9 26.826.8 25.025.0
개선도 총합total improvement 15.315.3 19.319.3 23.323.3 27.227.2 39.339.3 33.033.0 58.758.7 65.865.8 60.860.8
실험예 2. 섭취 방법 (용액 및 캅셀) 에 따른 체간 근기능 개선 효과 Experimental Example 2. Effect of improving trunk muscle function according to intake method (solution and capsule)
19~22 세의 대학교 남자 역도 선수 20명을 대상으로 조성물 8을 3가지 농도의 수용액 (1ppm, 20ppm 및 100ppm, 1회 200mL 섭취, 수용액 온도 15~25℃) 및 캅셀 (캅셀당 90mg, 1회 2 캅셀을 200mL의 상온수 (15~25℃)와 함께 섭취) 형태로 7일간 매일 기상 직후 및 취침 직전에 섭취하도록 한 후, 섭취 전과 비교했을 때의 체간 근기능 개선도를 평가하였다. For 20 male university male weightlifters aged 19-22 years, composition 8 was administered in 3 concentrations of aqueous solution (1ppm, 20ppm and 100ppm, 200mL ingestion at a time, aqueous solution temperature 15~25℃) and capsules (90mg per capsule, 1time) 2 capsules were taken in the form of 200mL of room temperature water (15~25℃) every day for 7 days immediately after waking up and right before going to bed, and the improvement of trunk muscle function compared to before intake was evaluated.
체간 근기능(Trunk muscle function) 측정은 Humac NORM(CSMi Co., U.S.A)을 이용하였으며, 측정에 앞서 보다 정확한 값을 얻기 위해 연구 대상자들에게 측정방법을 사전에 숙지 할 수 있도록 충분히 설명하고 측정 전 5~10분간 자유롭게 준비운동을 실시하였다. 측정시 신체의 부적절한 움직임을 방지하기 위해 스트랩(Strap), 벨트(Belt) 및 고정패드(Fixed pad)를 이용하여 가슴(Chest), 골반(Pelvic), 무릎(Knee)을 단단히 고정시켰다. 측정시 신체 질량에 의한 중력이 반영되지 않도록 중력보정(Gravity reduction)을 실시하였으며, 측정시 관절가동범위(Range of motion, ROM) 는 폄(Extension) -10°¡Æ에서부터 굽힘(Flexion) 60°로 설정하였다. 체간의 굽힘 및 폄 근력은 30°/sec 4회, 60°/sec 4회, 90°/sec 4회 실시하였으며, 체중 당(Percent body weight, %BW) 최대우력(Peak torque, Nm)을 측정하였다. 각각의 각속도 당 4회씩 적응 연습을 실시하였으며, 측정간 휴식시간은 20초로 설정하였다. To measure trunk muscle function, Humac NORM (CSMi Co., USA) was used, and in order to obtain a more accurate value prior to measurement, it was sufficiently explained to the study subjects so that they could familiarize themselves with the measurement method in advance. Warm-up exercises were performed freely for ~10 minutes. In order to prevent inappropriate movement of the body during measurement, the chest, pelvic, and knee were firmly fixed using a strap, a belt, and a fixed pad. Gravity reduction was performed so that gravity caused by the body mass was not reflected during measurement, and the range of motion (ROM) during measurement was extended from -10°¡Æ to flexion 60°. was set to Trunk flexion and extension strength were measured 4 times at 30°/sec, 4 times at 60°/sec, and 4 times at 90°/sec, and peak torque (Nm) was measured per body weight (%BW). did. Adaptation exercises were performed 4 times for each angular velocity, and the rest time between measurements was set to 20 seconds.
측정 결과를 표 5에 나타내었다. 용액으로 섭취할 경우, 캅셀 형태로 섭취하는 경우보다 우수한 효과를 보였으며, 조성물 사용량 측면에서 볼때, 900 배 적은 양을 사용하여도 더욱 우수한 효과가 나타났다. 또한 용액 섭취시에 조성물의 농도가 증가함에 따라 개선도가 증가하였으나, 20 ppm 이후에는 개선도 증가가 둔화되는 경향을 보였다. 따라서 본 발명의 조성물은 1~100 ppm 내외의 농도의 수용액으로 섭취하는 것이 캅셀 형태로 섭취하는 것에 비해 효과 뿐만 아니라 경제성 면에서 월등히 우수함을 알 수 있다.The measurement results are shown in Table 5. When ingested as a solution, it showed superior effects than when ingested in capsule form, and in terms of the amount of composition used, even better effects were obtained even when using a 900 times smaller amount. In addition, the improvement increased as the concentration of the composition increased when the solution was ingested, but after 20 ppm, the improvement showed a tendency to slow. Therefore, it can be seen that ingesting the composition of the present invention as an aqueous solution having a concentration of about 1 to 100 ppm is significantly superior in terms of economic efficiency as well as effect compared to ingestion in the form of capsules.
 섭취 제품Intake product 1ppm용액, 400mL1ppm solution, 400mL 20ppm용액, 400mL20ppm solution, 400mL 100ppm용액, 400mL100ppm solution, 400mL 90mg캅셀 x 4 90mgcapsules x 4
 조성물 9의 1일 섭취량Daily intake of composition 9 0.4 mg0.4 mg 8 mg8 mg 40mg40mg 360mg360mg
체간 굽힘 최대 우력 @30도/secTrunk flexion maximum force @30 degrees/sec 19.719.7 25.325.3 27.427.4 15.315.3
체간 폄 최대 우력 @30도/secTrunk extension maximum force @30 degrees/sec 18.818.8 23.123.1 24.924.9 14.214.2
체간 굽힘 최대 우력 @60도/secTrunk flexion maximum force @60 degrees/sec 19.119.1 24.724.7 22.222.2 13.413.4
체간 폄 최대 우력 @60도/secTrunk extension maximum force @60 degrees/sec 10.810.8 17.417.4 21.321.3 9.29.2
체간 굽힘 최대 우력 @90도/secTrunk Bend Maximum Couple @90 degrees/sec 22.622.6 27.927.9 29.029.0 15.315.3
체간 폄 최대 우력@90도/secTrunk extension max. force @90 degrees/sec 21.521.5 29.329.3 31.331.3 16.416.4
개선도 총점total improvement 112.5112.5 147.7147.7 156.1156.1 83.883.8
실험예 3. 섭취 방법에 따른 유연성 개선 효과 Experimental Example 3. Flexibility improvement effect according to intake method
19~23세의 남자 대학생 40명을 대상으로 조성물 9 을 일일 총 섭취량 10mg이 되는 4가지 다른 방법 (3가지 다른 용량 및 농도의 수용액 및 캅셀형태)으로 3일간 아침 기상 직후 및 저녁 취침 직전에 섭취 하였을 때, 섭취하지 않았을 때와 대비한 하지 유연성 (좌전굴) 개선효과를 비교하였다. Forty male college students aged 19-23 years, ingested Composition 9 immediately after waking up in the morning and just before going to bed in the evening for 3 days in 4 different ways (aqueous solution and capsule form of 3 different doses and concentrations) for a total daily intake of 10mg The effect of improving lower extremity flexibility (left flexion) was compared with that without intake.
결과를 하기 표 6에 나타내었다. 측정 결과, 캅셀로 섭취했을 경우에는 같은 양을 섭취하여도 효과가 거의 없었다. 용액 섭취 방법간 비교했을 때, 25~50 ppm 농도로 1회 섭취시 100~200 mL 의 용량으로 섭취했을 때 고농도로 소량 섭취 (100ppm, 50mL) 하는 경우에 비해 월등히 우수한 효과를 나타내었다. 따라서, 조성물 섭취시 최대 효과를 주기 위해서는 조성물이 위장관내에 고농도로 국부적으로 투여되는 것 보다는 조성물이 위장관내 전체에 고루 분포 되는 것이 더욱 효과적임을 알 수 있었다.The results are shown in Table 6 below. As a result of the measurement, when ingested in capsules, there was almost no effect even if the same amount was ingested. When compared between the solution intake methods, when ingested at a concentration of 25-50 ppm at a time, when ingested at a dose of 100-200 mL, the effect was significantly superior to that of a small intake (100 ppm, 50 mL) at a high concentration. Therefore, it was found that in order to give the maximum effect when ingesting the composition, it is more effective to distribute the composition evenly throughout the gastrointestinal tract rather than locally administering the composition at a high concentration in the gastrointestinal tract.
1일 총 섭취량 (mg)Total daily intake (mg) 10.010.0 10.010.0 10.010.0 10.010.0 10.010.0
수용액 내의 조성물의 농도 (ppm)Concentration of composition in aqueous solution (ppm) 100100 5050 33.333.3 2525 5mg 포함된 캅셀Capsules with 5mg
조성물 수용액 1회 섭취량 (mL)Serving amount (mL) of aqueous composition 5050 100100 150150 200200 물 150mL과 함께 섭취Take with 150mL of water
섭취전 대비 좌전굴 개선율 (%)Improvement rate of left abduction compared to before intake (%) 12.812.8 22.722.7 27.527.5 20.820.8 2.32.3
실험예 4. 섭취시점에 따른 운동 기능 개선 효과 Experimental Example 4. Effect of improving exercise function according to the time of intake
65세 이상 여성 노인들을 대상으로 일주일의 wash-out 기간을 두고 제품예 7 음료(25ppm 농도, 총 300mL)를 각각 일주일간 2가지 방식 - (1) 낮 시간 총 2회 (아침-점심 식간 1회, 점심-저녁 식간 1회) 및 (2) 아침기상직후+저녁취침직전 총 2회 - 으로 1회 150mL 씩 섭취하게 하고, 섭취전과 비교했을 때의 운동기능 개선도를 평가하였다. 결과를 표 7에 나타내었다. 결과적으로 방식 (2)의 경우가 월등이 우수한 개선 효과를 나타내었다. 따라서 인체 휴식기의 위장관 내에 조성물이 투입되는 것이 활동 시간에 투입되는 것 보다 더욱 효과적임을 알 수 있었다.For women aged 65 years and over, with a wash-out period of one week, product example 7 drinks (25ppm concentration, total 300mL) were administered in two ways for one week each - (1) Two times in the daytime (1 time between breakfast and lunch) , between lunch and dinner) and (2) immediately after waking up in the morning + before going to bed in the evening - twice a time, 150mL each, and the degree of improvement in motor function compared with before intake was evaluated. The results are shown in Table 7. As a result, the method (2) showed a superior improvement effect. Therefore, it was found that the injection of the composition into the gastrointestinal tract during the resting period of the human body is more effective than the input during the active period.
개선도%improvement % 섭취 방식 1Intake mode 1 섭취 방식 2Intake Mode 2
근력 (악력)strength (grip strength) 4.64.6 12.112.1
유연성(좌전굴)Flexibility (left flexion) 5.85.8 9.69.6
균형능력 (눈뜨고 외발서기)Balance ability (standing on one leg with eyes open) 3.73.7 8.88.8
개선도 총합total improvement 14.114.1 30.530.5
본 발명의 조성물은 경구 섭취를 통하여 근골격계의 기능을 종합적으로 개선시킴으로써 운동기능을 개선하는데 사용될 수 있고, 특히 본 발명의 제품을 섭취하는 경우 골밀도, 근육량, 유연성 및 평형감각이 총체적으로 개선되어 생활, 스포츠 및 예술 활동의 질을 높여줄 수 있다.The composition of the present invention can be used to improve exercise function by comprehensively improving the functions of the musculoskeletal system through oral intake, and in particular, when the product of the present invention is ingested, bone density, muscle mass, flexibility and sense of balance are overall improved, It can improve the quality of sports and artistic activities.

Claims (17)

  1. 플로로탄닌 화합물을 유효성분으로 포함하는 운동기능 개선용 조성물Composition for improving exercise function comprising a phlorotannin compound as an active ingredient
  2. 청구항 1에 있어서, 근골조직, 유연성 및 평형감각 중 하나 이상이 개선되는 것을 특징으로 하는 운동 기능 개선용 조성물The composition for improving motor function according to claim 1, wherein at least one of musculoskeletal tissue, flexibility, and sense of balance is improved.
  3. 청구항 1에 있어서, 근육량 및 골밀도 중 하나 이상을 개선시키는 것을 특징으로 하는 운동 기능 개선용 조성물The composition for improving exercise function according to claim 1, wherein at least one of muscle mass and bone density is improved.
  4. 청구항 1에 있어서, 상기 플로로탄닌 화합물은 하기 화학식 1 내지 12로 표시되는 플로로탄닌 중에서 선택되는 1종 이상인 것을 특징으로 하는 운동 기능 개선용 조성물The composition for improving exercise function according to claim 1, wherein the phlorotannin compound is at least one selected from phlorotannins represented by the following Chemical Formulas 1 to 12.
    [화학식 1][Formula 1]
    Figure PCTKR2021000645-appb-I000013
    Figure PCTKR2021000645-appb-I000013
    [화학식 2][Formula 2]
    Figure PCTKR2021000645-appb-I000014
    Figure PCTKR2021000645-appb-I000014
    [화학식 3][Formula 3]
    Figure PCTKR2021000645-appb-I000015
    Figure PCTKR2021000645-appb-I000015
    [화학식 4][Formula 4]
    Figure PCTKR2021000645-appb-I000016
    Figure PCTKR2021000645-appb-I000016
    [화학식 5][Formula 5]
    Figure PCTKR2021000645-appb-I000017
    Figure PCTKR2021000645-appb-I000017
    [화학식 6][Formula 6]
    Figure PCTKR2021000645-appb-I000018
    Figure PCTKR2021000645-appb-I000018
    [화학식 7][Formula 7]
    Figure PCTKR2021000645-appb-I000019
    Figure PCTKR2021000645-appb-I000019
    [화학식 8][Formula 8]
    Figure PCTKR2021000645-appb-I000020
    Figure PCTKR2021000645-appb-I000020
    [화학식 9][Formula 9]
    Figure PCTKR2021000645-appb-I000021
    Figure PCTKR2021000645-appb-I000021
    [화학식 10][Formula 10]
    Figure PCTKR2021000645-appb-I000022
    Figure PCTKR2021000645-appb-I000022
    [화학식 11][Formula 11]
    Figure PCTKR2021000645-appb-I000023
    Figure PCTKR2021000645-appb-I000023
    [화학식 12][Formula 12]
    Figure PCTKR2021000645-appb-I000024
    Figure PCTKR2021000645-appb-I000024
  5. 청구항 1에 있어서, 상기 조성물은 총 플로로탄닌 화합물을 0.001-100중량% 포함하는 것을 특징으로 하는 근골격계 기능 개선용 조성물The composition for improving musculoskeletal function according to claim 1, wherein the composition comprises 0.001-100% by weight of the total phlorotannin compound.
  6. 청구항 4에 있어서 상기 조성물은 화학식 1 내지 화학식 6 로 표시되는 플로로탄닌 중에서 선택되는 1종 이상, 화학식 7, 및 화학식 8 내지 화학식 12 로 표시되는 플로로탄닌 중에서 선택되는 1종 이상을 포함하는 것을 특징으로 하는 운동 기능 개선용 조성물The method according to claim 4, wherein the composition comprises at least one selected from phlorotannins represented by Chemical Formulas 1 to 6, and at least one selected from phlorotannins represented by Chemical Formula 7, and Chemical Formulas 8 to 12. Composition for improving motor function, characterized in that
  7. 청구항 1에 있어서, 상기 플로로탄닌 화합물이 대황(Eisenia bicyclis), 아이세니아 아르보레아(Eisenia arborea), 아이세니아 데스마레스티오데스(Eisenia desmarestioides), 아이세니아 갈라파제니스(Eisenia galapagensis), 아이세니아 매소니(Eisenia masonii), 검둥감태(Ecklonia kurome), 감태(Ecklonia cava), 곰피(Ecklonia stolonifera), 바다대나무(Ecklonia maxima), 에클로니아 라디아타(Ecklonia radiata), 에클로니아 바이시클리스(Ecklonia bicyclis), 에클로니아 바이런시네이트(Ecklonia biruncinate), 에클로니아 부시날리스(Ecklonia buccinalis), 에클로니아 카에파에스팁스(Ecklonia caepaestipes), 에클로니아 엑사스퍼타(Ecklonia exasperta), 에클로니아 파스티기아타(Ecklonia fastigiata), 에클로니아 브레빕스(Ecklonia brevipes), 에클로니아 아라보레아(Ecklonia arborea), 에클로니아 라티폴리아(Ecklonia latifolia), 에클로니아 무라티(Ecklonia muratii), 에클로니아 라디코사(Ecklonia radicosa), 에클로니아 리타디아나(Ecklonia richardiana) 및 에클로니아 라이티(Ecklonia wrightii)로 이루어진 그룹으로부터 선택된 1종 이상으로부터 추출되는 것을 특징으로 하는 근골격계 기능 개선용 조성물The method according to claim 1, wherein the phlorotannin compound is rhubarb (Eisenia bicyclis), Eisenia arborea (Eisenia arborea), Eisenia desmarestioides (Eisenia desmarestioides), Eisenia galapagensis (Eisenia galapagensis), Eisenia masonii, Ecklonia kurome, Ecklonia cava, Ecklonia stolonifera, sea bamboo (Ecklonia maxima), Ecklonia radiata, Ecklonia bicyclis ( Ecklonia bicyclis, Ecklonia biruncinate, Ecklonia buccinalis, Ecklonia caepaestipes, Ecklonia exasperta, Ecklonia pasti Ecklonia fastigiata, Ecklonia brevipes, Ecklonia arborea, Ecklonia latifolia, Ecklonia muratii, Ecklonia radicosa radicosa), Ecklonia richardiana (Ecklonia richardiana) and Ecklonia wrightii (Ecklonia wrightii) Composition for improving musculoskeletal system, characterized in that extracted from at least one selected from the group consisting of
  8. 청구항 1에 있어서, 플로로탄닌 화합물 0.1~100 ppm 농도의 20~50℃의 수용액으로 1회 10~200mL 섭취하는 것을 특징으로 하는 운동 기능 개선용 조성물The composition for improving exercise function according to claim 1, wherein 10 to 200 mL of the phlorotannin compound is ingested at a time in an aqueous solution of 20 to 50 °C with a concentration of 0.1 to 100 ppm.
  9. 청구항 8에 있어서, 상기 수용액을 공복에 섭취하는 것을 특징으로 하는 운동 기능 개선용 조성물The composition for improving exercise function according to claim 8, wherein the aqueous solution is consumed on an empty stomach.
  10. 청구항 1에 있어서, 플로로탄닌 화합물의 1일 사용량은 50kg 성인 기준 0.1~100 mg 인 것을 특징으로 하는 운동 기능 개선용 조성물The composition for improving exercise function according to claim 1, wherein the daily usage of the phlorotannin compound is 0.1 to 100 mg based on a 50 kg adult.
  11. 청구항 1의 운동 기능 개선용 조성물을 포함하는 운동 기능 개선용 제품A product for improving motor function comprising the composition for improving motor function of claim 1
  12. 청구항 11에 있어서, 상기 제품은 액상, 분말, 발포정 또는 단백질바(bar) 형태인 것을 특징으로 하는 운동 기능 개선용 제품The product for improving exercise function according to claim 11, wherein the product is in the form of a liquid, powder, effervescent tablet, or protein bar.
  13. 청구항 11에 있어서, 플로로탄닌 화합물 0.1~100 ppm 농도의 20~50℃의 수용액으로 1회 10~200mL 섭취하는 것을 특징으로 하는 운동 기능 개선용 제품The product for improving exercise function according to claim 11, wherein 10 to 200 mL of the phlorotannin compound is ingested at a time in an aqueous solution at 20 to 50° C. with a concentration of 0.1 to 100 ppm.
  14. 청구항 11에 있어서, 제품에 포함되는 플로로탄닌 화합물의 1일 사용량은 50kg 성인 기준 0.1~100 mg 인 것을 특징으로 하는 운동 기능 개선용 제품The product for improving exercise function according to claim 11, wherein the daily usage of the phlorotannin compound contained in the product is 0.1 to 100 mg based on a 50 kg adult.
  15. 청구항 11에 있어서, 플로로탄닌 화합물이 1~100 ppm 포함된 액상의 형태로 1일 10 ~2000mL 섭취하는 것을 특징으로 하는 운동 기능 개선용 제품The product for improving exercise function according to claim 11, wherein 10 to 2000 mL of phlorotannin compound is ingested in a liquid form containing 1 to 100 ppm per day.
  16. 청구항 15에 있어서, 상기 액상을 공복에 섭취하는 것을 특징으로 하는 운동 기능 개선용 제품The product for improving exercise function according to claim 15, wherein the liquid is consumed on an empty stomach.
  17. 청구항 11에 있어서, 근육량 및 골밀도 중 하나 이상을 개선시키는 것을 특징으로 하는 운동 기능 개선용 제품The product for improving exercise function according to claim 11, wherein at least one of muscle mass and bone density is improved.
PCT/KR2021/000645 2020-01-17 2021-01-18 Composition for improving athletic function, comprising phlorotannin as active ingredient WO2021145742A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR1020200006556A KR20210093408A (en) 2020-01-17 2020-01-17 Compositions comprising phlorotannin for improving musculoskeletal function
KR10-2020-0006556 2020-01-17
KR1020210005925A KR102594284B1 (en) 2021-01-15 2021-01-15 Compositions comprising phlorotannin for improving motor function
KR10-2021-0005925 2021-01-15

Publications (1)

Publication Number Publication Date
WO2021145742A1 true WO2021145742A1 (en) 2021-07-22

Family

ID=76863883

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2021/000645 WO2021145742A1 (en) 2020-01-17 2021-01-18 Composition for improving athletic function, comprising phlorotannin as active ingredient

Country Status (1)

Country Link
WO (1) WO2021145742A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080005711A (en) * 2006-07-10 2008-01-15 부경대학교 산학협력단 Composition containing phlorotannin for inhibition of matrix metalloproteinase activities
KR20150135136A (en) * 2014-05-23 2015-12-02 주식회사 비비에이치씨 Method for Preparing Induced Pluripotency Stem Cell from Mesenchymal Stem Cell Using Phlorotannin Fraction
KR20170050392A (en) * 2015-10-30 2017-05-11 주식회사 보타메디 Beverage composition comprising phlorotannin, ginseng extract and caffeine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080005711A (en) * 2006-07-10 2008-01-15 부경대학교 산학협력단 Composition containing phlorotannin for inhibition of matrix metalloproteinase activities
KR20150135136A (en) * 2014-05-23 2015-12-02 주식회사 비비에이치씨 Method for Preparing Induced Pluripotency Stem Cell from Mesenchymal Stem Cell Using Phlorotannin Fraction
KR20170050392A (en) * 2015-10-30 2017-05-11 주식회사 보타메디 Beverage composition comprising phlorotannin, ginseng extract and caffeine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KARADENIZ FATIH; AHN BYUL-NIM; KIM JUNG-AE; SEO YOUNGWAN; JANG MI-SOON; NAM KI-HO; KIM MIHYANG; LEE SANG-HYEON; KONG CHANG-SUK: "Phlorotannins suppress adipogenesis in pre-adipocytes while enhancing osteoblastogenesis in pre-osteoblasts", ARCHIVES OF PHARMACAL RESEARCH, NATL. FISHERIES UNIVERSITY , PUSAN, KR, vol. 38, no. 12, 23 July 2015 (2015-07-23), KR, pages 2172 - 2182, XP035958489, ISSN: 0253-6269, DOI: 10.1007/s12272-015-0637-0 *
OH JUNG HWAN, AHN BYUL-NIM, KARADENIZ FATIH, KIM JUNG-AE, LEE JUNG IM, SEO YOUNGWAN, KONG CHANG-SUK: "Phlorofucofuroeckol A from Edible Brown Alga Ecklonia Cava Enhances Osteoblastogenesis in Bone Marrow-Derived Human Mesenchymal Stem Cells", MARINE DRUGS, vol. 17, no. 10, 21 September 2019 (2019-09-21), pages 543, XP055828522, DOI: 10.3390/md17100543 *

Similar Documents

Publication Publication Date Title
Afifi Daily practices, study performance and health during the Ramadan fast
CN1119154C (en) Live triple bifidobacteria preparation and preparing method thereof
CN113398144B (en) Application of nucleotide mixture in preparation of preparation for preventing or relieving sarcopenia of old people
Olsen Lesions of peripheral nerves developing during coma
Strauss THE THERAPEUTIC USE OF VITAMIN B, IN POLYNEURITIS AND CARDIOVASCULAR CONDITIONS: CLINICAL INDICATIONS
WO2021145742A1 (en) Composition for improving athletic function, comprising phlorotannin as active ingredient
KR101859166B1 (en) A composition for removing hangover comprising an herb extract including ginseng
KR101689259B1 (en) Composition having effects of preventing or recovering fatigue or stress
PUROHIT et al. Multiple rib fractures due to physiotherapy in a neonate with hyaline membrane disease
KR102594284B1 (en) Compositions comprising phlorotannin for improving motor function
KR101046787B1 (en) Hangover drink composition
KR20010055274A (en) Health augmentation food for the anti fatigue
JPH05271063A (en) Agent for eliminating and removing active oxygen
KR20210093408A (en) Compositions comprising phlorotannin for improving musculoskeletal function
Corsello et al. Nutraceuticals and biotics in pediatric gastrointestinal disorders
Harrison et al. Pellagra caused by isoniazid
WO2012096475A2 (en) Composition for a functional food having the effect of restoring blood composition and function
CN101143203A (en) Compound oral liquid with liver-protecting and stomach-nourishing function
CN102362936A (en) Application of amorphophallus blume extract, and medicine and healthcare product solid preparation and beverage of amorphophallus blume extract
CN110720527A (en) Traditional Chinese medicine weight-losing tea
CN112057476B (en) Composition and application thereof in sobering-up, hangover-relieving and stomach-protecting
CN109601996A (en) A kind of composition and its application with auxiliary effect for reducing blood fat
CN114712424B (en) Traditional Chinese medicine preparation with effects of dispelling effects of alcohol and protecting liver as well as preparation method and application thereof
CN1537603A (en) Traditional Chinese medicine navel plaster, and its prepn. method
Hutchison The elements of medical treatment

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21741179

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21741179

Country of ref document: EP

Kind code of ref document: A1